UPCI Selected Active Grant Information
The below is a selected list of UPCI grants active as of August, 2005. Information on basic research programs, clinical research programs, and cancer control and population sciences research programs are also available in those programs' sections.
| PRINCIPAL INVESTIGATOR | FUNDING SOURCE | PROJECT TITLE | PROJECT PERIOD | FUNDING TOTAL | ||
|---|---|---|---|---|---|---|
| Agarwala | Sanjiv | Cell Therepeutics Inc | Phase II Study of Arsenic Trioxide ATO in Advanced Metastatic Melanoma | 5/2/07 | 7/1/10 | $39,097 |
| Agarwala | Sanjiv | Chiron Corp | A Phase II Trial of Sequential Temozolomide Chemotherapy Followed by High Dose Bolus IL 2 Immunotherapy for Metastatic Melanoma | 9/11/08 | 9/10/12 | $32,656 |
| Agarwala | Sanjiv | Covance | A Phase 2 Study of STA 4783 in Combination with Weekly Paclitaxel fro Treatment of Patients with Soft Tissue Sarcomas UPCI 04057 | 8/18/08 | 8/17/10 | $27,030 |
| Agarwala | Sanjiv | Enzon | An Evaluation of the Efficacy and Safety of PEG Camptothecin in the Treatment of Advanced or Metatstatic Soft Tissue Carcinoma | 1/10/08 | 1/9/13 | $31,500 |
| Agarwala | Sanjiv | Genetics Institute | ICC2302 Phase II Trial of Combrestatin A 4 Phosphate CA4P in Advanced Anaplastic Carcinoma of the Thyroid | 4/27/08 | 4/26/10 | $53,625 |
| Agarwala | Sanjiv | Human Genome Sciences | Pharmacokinetics and Pharmacodynamics Albeleukin | 8/14/06 | 8/13/09 | $65,691 |
| Agarwala | Sanjiv | Luitpold | Phase III Study of Taxoprexin Injection vs Dacarbazine in Patients with Metastatic Melanoma | 11/22/07 | 11/19/10 | $25,750 |
| Agarwala | Sanjiv | Maxim Pharm | A Multicenter Study to Determine tye Safety of Interleukin 2 IL Plus Histamine Dihydrochloride for Injection HDC in Subjects with AJCC Stage IV Malignant Melanoma | 9/25/08 | 9/24/12 | $39,063 |
| Agarwala | Sanjiv | Maxim Pharmaceuticals | Maxim Study | 4/10/06 | 4/9/09 | $130,791 |
| Agarwala | Sanjiv | Point Therapeutics | An Open Label Phase 2 Trial of PT 100 in Patients with Metastatic Melanoma | 12/22/08 | 12/21/09 | $91,964 |
| Agarwala | Sanjiv | Schering Plough | Extended Schedule escalated Dose Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma A Randomized Phase III Study of the EORTC Melanoma Group | 7/14/08 | 6/13/13 | $20,050 |
| Ahearn | Joseph | Arthritis Foundation | Erythrocyte Bound Complement as a Novel Biomarker of Disease | 3/2/07 | 3/1/09 | $66,000 |
| Ahearn | Joseph | NIH | Complement, Cardiovascular Disease and SLE | 10/1/07 | 6/1/11 | $311,078 |
| Ahearn | Joseph | NIH | Erythrocytes as Time Capsules of Disese Activity in SLE | 7/2/07 | 7/1/12 | $310,250 |
| Ahearn | Joseph | NIH | Vasculopathy, Apoptosis and Autoimmunity | 9/28/03 | 9/1/09 | $217,875 |
| Altschuler | Daniel | IPA-Design Environmentally Sensitive Murine Thyroid Cancer Model Based on Expression of Mutated RAP | 5/2/07 | 5/1/09 | $73,501 | |
| Altschuler | Daniel | NCI | Transduction of Camp Signal by Rap 1 | 3/13/08 | 3/1/13 | $301,050 |
| Altschuler | Daniel | NIH | Rap 1B a Mitogenic Signal in Thyroid | 7/2/07 | 6/1/11 | $327,615 |
| Amoscato | Andrew | NCI | Radiation-Induced Ceramide Generation | 4/2/07 | 4/1/11 | $264,553 |
| Apodaca | Gerard | American Heart Association (National) | Endocytic Recycling in Kidney Cells | 1/2/07 | 1/1/12 | $50,000 |
| Apodaca | Gerard | NIH | Endocytic and Exocytic Traffic in Bladder Uroepithelium | 5/2/08 | 5/1/13 | $325,799 |
| Apodaca | Gerard | NIH | Regulaton of Endocytic Traffic in Kidney Cells | 12/2/00 | 12/1/09 | $149,664 |
| Arndt | Karen | NIH | Transcription Factors Mutants of Yeast | 12/02/08 | 12/01/12 | 324,803 |
| Arndt | Karen | NIH | Transcription Factors Mutants of Yeast | 09/02/04 | 09/01/09 | $100,602 |
| Arnold | Robert | NCI | Enhancing Patient-Oncologist Communication | 5/2/07 | 4/1/12 | $69,310 |
| Arnold | Robert | NIH/NCI | End of Life Communication Skills for Oncology Fellows | 9/2/05 | 9/1/10 | $22,913 |
| Arnold | Robert | Valley Care Association | Advanced Illness Coordinated Care Project | 9/2/07 | 6/1/09 | $17,316 |
| Asher | Sanford | NIH | UV Resonance Raman Studies of protein Structure | 9/2/01 | 9/1/11 | $307,489 |
| Auron | Philip | NCI | Acessory Cell Activation of the Immune Response | 8/26/99 | 6/1/09 | $233,953 |
| Ayyavoo | The Campbell Foundation | Evaluation of Novel Antivirals Targeting HIV-1 Vpr | 7/2/08 | 7/1/09 | $60,000 | |
| Baar | Joseph | Chiron Corp | A Phase II Clinical Trial of High Dose Interleukin 2 HDIL2 and Thalidomide in Patients with Metastatic Rebal Cell Cercinoma | 11/5/08 | 11/10/12 | $62,500 |
| Baar | Joseph | Orthobiotech | Phase II Clinical Trial of Gemcitabine and DOXIL for Metatstatic Renal Cell Carcinoma | 5/12/08 | 5/11/10 | $57,650 |
| Baar | Joseph | Susan G. Komen | Enhancement of Dendritic Cell Based Breast Cancer Vaccines by Chemotherapy | 5/2/07 | 5/1/09 | $58,560 |
| Baar | Joseph | Wyeth Ayerst | A Phase III Three Arm Randomized Open Label Study of Interferon Alfa Alone CCI 779 Alone and the Combination of Interferon Alfa and CCI 779 in First Line Poor Prognosis Subjects with Advanced Renal Cell Carcinoma | 11/5/07 | 11/4/11 | $30,431 |
| Bahar | Ivet | NIH | Multiscale Dynamics of Cell Cycle Control and Apoptosis-TOTALS | 08/02/07 | 08/01/10 | 328,539 |
| Bahar/Bahar | Ivet | NIH | Multiscale Dynamics of Cell Cycle Control and Apoptosis-Main Project | 08/02/07 | 08/01/10 | |
| Bahar/Bahar | Ivet | NIH | Multiscale Dynamics of Cell Cycle Control and Apoptosis-Core (tools and education) | 08/02/07 | 08/01/10 | |
| Bahar/Billiar | Ivet | NIH | Multiscale Dynamics of Cell Cycle Control and Apoptosis-Development Project 1 | 08/02/07 | 08/01/10 | |
| Bahar/Lazo | Ivet | NIH | Multiscale Dynamics of Cell Cycle Control and Apoptosis-Development Project 3 | 08/02/07 | 08/01/10 | |
| Bahar/Wood | Ivet | NIH | Multiscale Dynamics of Cell Cycle Control and Apoptosis-Development Project 2 | 08/02/07 | 08/01/10 | |
| Barnard | David | NCI | Undergraduate Medical Education for End of Life Care | 6/2/05 | 6/1/09 | $220,630 |
| Barnard | David | NIH/NCI | Undergraduate Medical Education for End of Life Care | 6/2/05 | 6/1/10 | $182,922 |
| Barratt-Boyes | Simon | NIH | Whole Autologous SIV Vaccine Using Dendritic Cells | 4/2/06 | 4/1/11 | $359,690 |
| Bartlett | David | NCI | Development of a Tumor Selective Replicating Vaccinia | 3/2/08 | 2/29/12 | $297,983 |
| Bartlett | David | The Pittsburgh Foundation | Isolated Hepatic Perfusion with Oxaliplatin for Colorectal Liver Matastases | 7/16/06 | 6/15/09 | $46,340 |
| Basse | Per | ACS | Treatment Of Lung Malignancies With Prodrug Activating Natural Killer Cells | 1/2/08 | 1/1/12 | $180,000 |
| Basse | Per | NCI | Cytokine Delivery By Tumor Seeking Lymphocytes | 3/3/08 | 3/1/11 | $224,956 |
| Baum | Andrew | Jewish Healthcare Fn | Pain Management In Cancer Researching the Value of Psychological Interventions | 10/2/08 | 10/1/09 | $36,000 |
| Baum | Andrew | NIH | Child Neglect Psychological Conseq | 9/2/05 | 9/1/09 | $5,719 |
| Baum | Andrew | NIH | Excellence In Partnerships for Community Outreach Research on Health Disparities | 10/1/08 | 8/1/09 | $12,629 |
| Baum | Andrew | DOD | Center for Biobehavioral Research and Breast Cancer | 9/2/05 | 9/1/09 | $1,006,012 |
| Baum/Baum | Andrew | DOD | Center for Biobehavioral Research and Breast Cancer-Core A | 9/2/05 | 9/1/09 | |
| Baum/Baum | Andrew | DOD | Center for Biobehavioral Research and Breast Cancer-project 1 | 9/2/05 | 9/1/09 | |
| Baum/Baum | Andrew | DOD | Center for Biobehavioral Research and Breast Cancer-project 3 | 9/2/05 | 9/1/09 | |
| Baum/Baum | Andrew | DOD | Center for Biobehavioral Research and Breast Cancer-trainee | 9/2/05 | 9/1/09 | $229,797 |
| Baum/Jenkins | Andrew | DOD | Center for Biobehavioral Research and Breast Cancer-Core B | 9/2/05 | 9/1/09 | |
| Becich | Michael | NCI | A Shared Tissue Resource for Molecular Classification of Prostate Cancer | 5/27/04 | 4/1/09 | $649,202 |
| Becich | Michael | NCI | Subcontract from Indiana University on Grant Indiananapolis Pathology Informatics Network | 8/14/05 | 8/1/10 | $281,140 |
| Becich | Michael | NIH | caBIG Working Group Participation | 7/16/08 | 3/8/13 | $1,959,544 |
| Becker | Dorothea | NCI | Spectral Imaging Of Melanoma Cell Adhesion And Metastasis Formation | 4/2/07 | 4/1/12 | $352,690 |
| Beckner | Wichman Foundation | Suppression of Invasive Astrocytoma Cell Migration | 3/2/08 | 3/1/09 | $40,000 | |
| Belani | Chandra | A Phase I Dose Escalation Trial of KOS 862 in Combination with Gemcitabine in Patients with Advanced Malignancies | 4/23/08 | 4/22/11 | $64,156 | |
| Belani | Chandra | Amgen | Protocol 20030123 Pegfilgrastim Given Same Day….Non Small Lung Cancer | 10/16/07 | 10/15/10 | $10,416 |
| Belani | Chandra | Astra Zeneca | A Randomized Open Label Parallel Group International Multicenter Phase II Study of Oral ZD1839 IRESSA…..Non Small Cell Lung Cancer Who Have Previously Rece… | 11/9/08 | 11/8/12 | $55,188 |
| Belani | Chandra | Astra Zeneca | Phase II Study to Asses the Safety, Tolerability, and Efficacy of ZD6474 | 12/31/06 | 12/13/09 | $45,376 |
| Belani | Chandra | Astra Zeneca | Retrospectice Chart Review of IRESSA Expanded Access Program EAP Trial Number | 12/2/07 | 12/1/09 | $50,000 |
| Belani | Chandra | Aventis | Phase II Trial of Gemcitabine and Docetaxel…. Small Cell Lung Cancer | 9/2/07 | 9/1/09 | $50,125 |
| Belani | Chandra | Biomeasure, Inc | A Phase II Open Label Study Investigating the Activity of Diflomotecan BN80915 Administered at the Fixed Rate Dose of 7MG as a 20 Minute Intravenousinfusion Once Every 3 Weeks in Patients With Sensitive Small Cell Lung Cancer SCLC with Progressive DI | 7/1/08 | 11/1/09 | $62,423 |
| Belani | Chandra | Bristol Myers Squibb | A Phase I Study of BMS 275183 Given on a Daily Schedule in Patients With Advancved Malignancies | 11/2/08 | 11/1/10 | $75,688 |
| Belani | Chandra | Genentech Inc | A Phase II Multicenter Randomized Clinical Trial to Evaluate the Efficacy and Safety of Avastin Bevacizumab in Combination with Docetaxel or Tarceva Erlotinib Hydrochlroide Compared with Docetaxel Alone for Treatment of Reccurrent or Refractory Non Sm…. | 10/27/08 | 10/26/12 | $37,410 |
| Belani | Chandra | Glaxosmithkline | A Phase I Study to Determine the Safety and Pharmacokinetics of Intravenous Administration of SB 743921 on a Once Every 3 Week Schedule in Patients with Solid Tumors | 6/17/08 | 6/16/09 | $264,895 |
| Belani | Chandra | Hoffman La Roche | An Open Label Randomized Multicenter Phase II Study to Determine Hemoglobin Dose Response…. | 11/1/07 | 10/31/10 | $63,534 |
| Belani | Chandra | Lilly Res Labs / IGATE | A Phase I and Pharmacokinetic Study of Gemcitabine in Combination with Oxaliplatin and Capecitbine in Advanced Solid Tumors | 4/22/08 | 5/1/12 | $63,000 |
| Belani | Chandra | Lilly Res Labs / IGATE | ALIMTA Plus Gemcitabine as Front Line Chemotherapy…A Phase II Clinical Trial 02 108 | 4/22/08 | 5/1/10 | $19,500 |
| Belani | Chandra | NCI | Phase I Clinical Trials of Novel Anticancer Agents | 3/2/07 | 2/1/12 | $414,235 |
| Belani | Chandra | NCI | The University of Texas SPORE in Lung Cancer LCBCC Supplement | 5/2/08 | 5/1/09 | $97,454 |
| Belani | Chandra | Novartis | An Open Label Phase I II Dose Escalating the Safety and Efficacy of EP0906 q3w in Patients with Non Small Cell Lung Cancer | 6/13/07 | 6/1/09 | $43,787 |
| Belani | Chandra | PCRN | Clinical Trial of ABX EGY in Combination with Paclitaxel | 1/9/06 | 1/8/09 | $170,582 |
| Belani | Chandra | PCRN | Evaluation of Celecoxib in Combination with Carboplatin and Irinotecan | 6/2/06 | 6/1/09 | $56,940 |
| Belani | Chandra | PCRN | Intrapleural Gemcitabine Therapy for Mailgnant Pleural | 9/2/06 | 9/1/09 | $50,000 |
| Belani | Chandra | PCRN | Phase I Open Label Study of the Combination of Gleevac ST1571 with Cisplatin and Etoposide for Previously Unreated Extensive Stage Small Cell Lung Cnacer UPCI | 1/2/06 | 7/1/09 | $30,386 |
| Belani | Chandra | PCRN | Phase II Study of Irinotecan and Paciltaxel | 7/2/06 | 12/1/09 | $74,386 |
| Belani | Chandra | PCRN | Phase II Trial of Irinotecan as Second Line Chemotherapy | 8/22/06 | 8/21/09 | $74,960 |
| Belani | Chandra | Pfizer | Phase I Evaluation of Oral CI 1033..in Lung or Ovarian Cancer | 4/16/07 | 4/15/10 | $50,862 |
| Belani | Chandra | Pharm Res Assoc Inc | A Phase 2 Efficacy and Safety Study of SUO11248 in Patients With Metastatic Non Small Cell Lung Cancer | 11/17/08 | 11/16/12 | $71,798 |
| Belani | Chandra | Pharmacia & Upjohn | Randomized Double Blind Phase II Trial of Preoperative Celecoxib Paclitaxel Carboplatin for Stage III A Non Small Cell Lung Cancer | 1/9/08 | 1/1/12 | $16,668 |
| Belani | Chandra | Pharmacyclics Inc | Study of Motefaxin Gadolinium with Radiation and Chemotherapy | 2/6/07 | 3/1/09 | $38,666 |
| Belani | Chandra | Schering Plough | Randomized Double Blind Placebo Controlled Phase 3 Study of Temozolomide or Placebo Added to Whole Brain Radiation Therapy for the Treatment of Brain Metastases from Non Small Cell Lung Cancer | 6/15/08 | 6/15/12 | $19,988 |
| Belani | Chandra | Schering Plough Inc | Phase III…Lonafarnib in Combination with Paclitaxel | 3/2/07 | 3/1/11 | $25,937 |
| Belani | Chandra | Wyeth | Phase I Dose Escalation Study of MAC 321 | 6/2/07 | 6/1/10 | $ |
| Belani | Chandra | Wyeth | Phase II. MAC321 for Non Small Cell Lung cancer | 6/2/07 | 6/1/10 | $42,153 |
| Belani | Chandra | A Phase I Dose Escalation Trial of KOS 862 in Combination with Gemcitabine in Patients with Advanced Malignancies | 4/23/08 | 4/22/11 | $64,156 | |
| Bender | Catherine | Organon | A Pilot Study of a Double-Blind, Placebo-Controlled Clinical Trial of Mirtazapine for the Prevention of Depression Associated with High-Dose Interferon Therapy in Patients with Melanoma | 9/2/06 | 9/1/10 | |
| Benos | Pagianatos | NSF | Quantitative modeling of protein DNA binding specificity | 9/2/07 | 9/1/10 | $130,058 |
| Bigbee | William L. | NCI | Serum Proteomic Biomarkers for Colon and Pancreatic Cancer | 9/23/08 | 9/1/13 | $187,598 |
| Bigbee | William L. | NIH/NCI | UPCI Cancer Education and Career Development Programs | 2/2/05 | 4/1/09 | $322,354 |
| Bigbee | William L. | Snee Reinhardt Charitable Fdtn | Proteomics Instrumentation | 1/2/08 | 1/1/09 | $246,000 |
| Billiar | Timothy | NIH | Nitric Oxide and Hepatic Function in Sepsis and Trauma | 7/2/07 | 7/1/12 | $295,301 |
| Billiar | Timothy | NIH | Post Traumatic Sepsis: | 1/2/98 | 4/1/10 | 235,281 |
| Billiar | Timothy | NIH | Training in Trauma and Sepsis Research | 07/02/98 | 07/01/13 | $294,063 |
| Billiar | Timothy | NIH | Molecular Biology of Hemorrhagic Shock; TOTALS | 07/02/08 | 07/01/13 | 0 |
| Billiar/Bauer | Timothy | NIH | Molecular Biology of Hemorrhagic Shock; Project III | 07/02/08 | 07/01/11 | |
| Billiar/Billiar | Timothy | NIH | Molecular Biology of Hemorrhagic Shock; Core A | 07/02/08 | 07/01/13 | |
| Billiar/Billiar | Timothy | NIH | Molecular Biology of Hemorrhagic Shock; Core B | 07/02/08 | 07/01/13 | |
| Billiar/Billiar | Timothy | NIH | Molecular Biology of Hemorrhagic Shock; Project I | 07/02/08 | 07/01/13 | |
| Billiar/Fink | Timothy | NIH | Molecular Biology of Hemorrhagic Shock; Project II | 07/02/08 | 07/01/13 | |
| Billiar/Pitt | Timothy | NIH | Molecular Biology of Hemorrhagic Shock; Project IV | 07/02/08 | 07/01/13 | |
| Billiar/Vodovotz | Timothy | NIH | Molecular Biology of Hemorrhagic Shock; Project V | 07/02/08 | 07/01/13 | |
| Billiar/Watkins | Timothy | NIH | Molecular Biology of Hemorrhagic Shock; Core C | 07/02/08 | 07/01/13 | |
| Boada | Fernando | ICON | Leade Study | 3/2/07 | 3/1/10 | $1,119 |
| Boada | Fernando | NARSAD | Affective Neuroscience of Information Processing in Depression (Siegel) | 7/2/05 | 7/1/09 | $3,279 |
| Boada | Fernando | NIH | Cognitive and Affective Neuroscience of Depression | 5/16/06 | 5/1/09 | $18,752 |
| Boada | Fernando | NIH | Ischemic Brain Damage and Triple/Single Quantum Sodium MRI | 4/2/07 | 4/1/09 | $195,563 |
| Boada | Fernando | NIH | Multi-Tracer Pet Quantitation of Insulin Action in Muscle Phase 2 | 5/16/06 | 5/1/09 | $9,894 |
| Boada | Fernando | NIH | Psychobiology of Suicidal Behavior in BPD (Soloff) | 7/2/05 | 6/1/09 | $7,097 |
| Boada | Fernando | Wyeth Ayerst | Safety Tolerability and Pharmacokinetic Study of ASB001 in Alzheimers Disease | 1/31/08 | 11/1/09 | $12,213 |
| Branch | Robert | NCI | Drug Metabolizing Enzymes-Risk Factors in Bladder Cancer | 7/7/05 | 7/1/09 | $406,508 |
| Branch | Robert | NIH | Drug Metabolism in Chronic Liver Disease | 9/16/06 | 7/1/10 | $209,553 |
| Brickner | Anthony | Amer Society of Hematology | Identification and Characterization of Human Minor Histocompatibility Antigen Targets of the Graft Vs Leukemia Effect | 7/2/08 | 7/1/10 | $75,000 |
| Brickner | Anthony | LSLF | Identification Of Graft Vs Leukemia Associated Human Minor Histocompatibility Antigens | 1/2/08 | 1/1/09 | $17,500 |
| Brickner | Anthony | National Marrow Donor Program | Identifying Graft Versus Leukemia Associated Human Minor Histocompatibility Antigens Restricted By HLA A2 | 7/2/08 | 7/1/11 | $80,000 |
| Brodsky | Jeffrey | NCI | Modulators of T antigen-mediated chaperone action | 8/2/07 | 8/1/09 | $146,366 |
| Brodsky | Jeffrey | NIH | Molecular Regulation of Apoprotein B Degradation | 7/2/06 | 7/1/11 | $38,629 |
| Brodsky | Jeffrey | NSF | Colloborane Research: Protein Quality Control in the Endoplastic Reticulum | 8/16/05 | 8/1/09 | $198,344 |
| Brown | Charles | Hillman Foundation | Targeted Imaging of Cancer Through Peptide Guided Magnetic Resonance Imaging | 7/2/08 | 7/1/10 | $125,000 |
| Brufsky | Adam | AMGEN | A Randomized Active Controlled Study of AMG 162 in Breast Cancer Subjects with Bone Metastases who have not been Previously Treated with Bisphosphorate Therapy | 8/10/08 | 8/9/12 | $22,193 |
| Brufsky | Adam | AMGEN | A Randomized Active Controlled Study of AMG 162 in Subjects with advanced Cancer Currently Being Treated with Intarvenous Bisphosphonates | 9/8/08 | 9/7/12 | $19,313 |
| Brufsky | Adam | Astra Zeneca | Randomized Double Blind Study to compare the efficacy….inhibitor therapy | 12/13/07 | 12/12/10 | $27,000 |
| Brufsky | Adam | Aventis | A Randomized Open Label Phase III Study of RPR 109881 IV…. After Taxanes and Anthracycline Therapy | 8/18/08 | 8/17/12 | $32,329 |
| Brufsky | Adam | Bristol Myers Squibb | A Phase II Trial of Novel Epothilone BMS 247550 in Patients with Advanced Breast Cancer Who Are Resistant to an Anthracycline a Taxane and Capecitabine UPCI | 7/22/08 | 7/21/10 | $27,575 |
| Brufsky | Adam | Bristol Myers Squibb | A Phase III Trial of Novel Epothilone BMS 247550 Plus Capecitabine Versus Capecitabine Alone in Patients with Advanced Breast Cancer Previously Treated with or Resistant to an Anthracycline and who are Taxane Resistant CA 163046143 | 7/22/08 | 7/21/11 | $41,008 |
| Brufsky | Adam | Carolinas | A Phase II Study to Compare the Neoadjuvant Administration of Taxotere and Navelbine or Taxotere Followed by Adriamycin and Cytoxan with all Chemotherapy Administered in a Dose Dense Fashion to Women with Stage II and Stage III Breast Cancer | 5/2/08 | 5/9/11 | $65,000 |
| Brufsky | Adam | DOD | The Pittsburgh Breast Cancer Consortium | 08/02/05 | 09/01/09 | 121,734 |
| Brufsky | Adam | EISAI AM INC | An Open Label Phase II Study of E7070 in Metastatic Breast Cancer Patients Previously Treated with an Anthracycline a Taxane and Capecitabine | 09/03/08 | 08/31/12 | 27,993 |
| Brufsky | Adam | Genentech Inc | RegistHER An Observational Cohort Study of HER 2 Positive Metastatic Breast Cancer Patients Protocol H2757n | 9/9/08 | 1/1/13 | $7,969 |
| Brufsky | Adam | Glaxosmithkline | Phase II Open Label Study of SB715992 in Subjects with Advanced or Metastatic Breast Cancer | 6/14/08 | 6/15/13 | $16,791 |
| Brufsky | Adam | NAFTA | Phase III Study of Tamoxifen vs. Torexifen as Adjuvant Therapy | 11/2/05 | 10/31/10 | $4,800 |
| Brufsky | Adam | NCI | Educational Resourse for Tumor Heterogeneity | 09/02/04 | 09/01/09 | 28,008 |
| Brufsky | Adam | Novartis | Use of Zoleronic Acid in Prevention of Cancer Treatment Related Bone Loss | 8/2/06 | 8/31/12 | $12,614 |
| Brufsky | Adam | Ohio St U | Phase II Trial of Anti HER2 Monoclonal Antibody Herceptin…Breast Cancer Patients | 4/2/07 | 6/1/09 | $7,250 |
| Brufsky | Adam | Ortho Biotech Inc | A Randomized Open Label Study of Epoetin Alfa Procrit Versus Darbepoetin Alfa Aranesp….Patients Receiving Chemotherapy | 2/10/08 | 2/9/11 | $20,334 |
| Brufsky | Adam | PRA | An Open Label Multicenter Single Arm Phase II Study Of Oral GW572016 As A Single Agent Therapy In Subjects With Advanced Or Metastatic Breast Cancer Who Have Progressed While Receiving Herceptin Containing Regimens | 10/26/07 | 10/28/10 | $25,159 |
| Brufsky | Adam | PRA | Protein Autovac PX104 1 6 In Patients With Breast Cancer Protocol PX 104 1 6 101 | 6/28/07 | 6/27/10 | $10,819 |
| Brufsky | Adam | SGK | Magnetic Resonance Spectroscopic Imaging | 01/03/08 | 09/01/09 | 16,520 |
| Brufsky | Adam | Taiho Pharm | A Phase II Randomized Double Blinded Efficacy and Safety Study of Three Doses of TAS 108 Administered Orally….Breast Cancer Carcinoma Following Standard… | 7/2/08 | 7/1/11 | $45,693 |
| Brufsky | Adam | Wyeth Ayerst | A Phase 3 Ramdomized Placebo Controlled Double Blind Study of Oral CCI 779…..Metastatic Breast Cancer | 5/1/08 | 4/30/12 | $34,199 |
| Brufsky | Adam | Xanthus | Amonafide Individual Phenotype Adjusted Chemotherapy for Women with Metastatic Breast Cancer Who Have Progressed Despite Prior Chemotherapy | 2/10/08 | 2/9/10 | $57,739 |
| Bryant | John | NCI | Biostatistical Center Prevention | 6/2/05 | 6/1/10 | $4,904,981 |
| Bryant | John | NSABP | Iressa Trial | 10/2/06 | 5/1/10 | $42,990 |
| Bunker | Clareann | NCI | Molecular Epidemiology of Prostate Cancinogenesis | 9/30/99 | 8/1/09 | $39,438 |
| Butterfield | Lisa | Am Heart | AFP Based Immunotherapy of Hepatocellular Cancer | 10/2/07 | 12/13/10 | $86,664 |
| Butterfield | Lisa | Hillman Foundation | Determinant Spreading in Melanoma Immunotherapy | 7/2/08 | 7/1/10 | $100,000 |
| Butterfield | Lisa | NCI | AFP Based Immunotherapy of Hepatocellular Cancer | 7/27/08 | 7/1/11 | $304,425 |
| Butterfield | Lisa | RAID Project 447 Plasmid Adenovirus Assay | 10/2/08 | 10/1/09 | $9,052 | |
| Byrne | Margaret | NIH/NCI | Resource and QOL consequence of lung cancer screening | 8/9/07 | 8/1/12 | $130,274 |
| Carlos | Timothy | Aventis | Educational Scientific Activities Grant | 12/8/05 | 12/7/10 | $134,122 |
| Carlos | Timothy | Aventis | Educational Scientific Activities Grant | 12/8/05 | 12/7/10 | $600,000 |
| Carlos | Timothy | Aventis | Educational Scientific Activities Grant | 12/8/05 | 12/7/10 | $665,000 |
| Carlos | Timothy | Quintiles | An Open Lable 12 month 48 week Extension Study Evaluating the Long Term Safety and Continued Benefits of ICA 17043 with or without Hydroxyurea | 2/14/07 | 2/1/09 | $7,380 |
| Carr | Brian | Cell Therapeutics, Inc. | A Phase II Study of Trisenox and Ascorbic Acid in hepatocellular Carcinoma | 10/16/07 | 10/15/12 | $230,000 |
| Carr | Brian | DataMedix Corporation | Consulting Services in Support of Clinical Development of TheraSphere | 3/2/05 | 3/1/09 | $12,500 |
| Carr | Brian | MDS Nordion | Support of Clinical Development and Diffusion of Therasphere | 6/22/06 | 6/21/10 | $60,000 |
| Carr | Brian | MDS Nordion | The Use of Therasphere Yttrium-90 for Treatment of Unresectable Hepatocellular Carcinoma | 8/2/04 | 3/23/10 | $180,000 |
| Carr | Brian | NCI | K vitamins- a new class of liver cell growth inhibitors | $267,300 | ||
| Carroll | Michael | Johnson & Johnson | An Open Label Phase 2 Study Of The Faresyl Transferase Inhibitor Zarnestra R115777 As Postconsolidation Therapy For Acute Myeloid Leukemia AML In Subjects 60 Years and Older | 9/10/07 | 9/9/10 | $21,575 |
| Cascio | Michael | NIH | Dopamine Toxicity and Mitochondrial Dysfunction | 7/2/06 | 7/1/11 | $61,034 |
| Cascio | Michael | NIH | Protein Dopamine Adducts in Methamphetamine Toxicity | 12/3/05 | 9/1/09 | $6,244 |
| Cascio | Michael | NIH | Protein Dopamine Adducts in Methamphetamine Toxicity | 12/3/05 | 9/1/09 | $46,830 |
| Cauley | Jane | Cal Pac Med Ctr | Study of Osteoporotic Fractures - Sleep Study | 10/1/05 | 8/1/09 | $30,132 |
| Cauley | Jane | Kaiser Res Inst | Mammographic Density in a Multi-Ethnic Cohort | 7/16/06 | 7/1/10 | $76,489 |
| Cauley | Jane | Lilly | Continuing Outcomes Relevant to Evista | 12/2/03 | 12/1/09 | $71,813 |
| Cauley | Jane | Lilly | Raloxifene in Women at Risk for Cardiovascular Events | 9/2/02 | 9/1/09 | $707,038 |
| Cauley | Jane | Merck | Measuring the Effects of Fosamax on Bone Structure | 1/2/09 | 1/1/12 | $27,600 |
| Cauley | Jane | NIH | Osteoporotic Fractures in Men | 10/1/03 | 7/1/10 | $512,912 |
| Cauley | Jane | NIH | Outcomes of Sleep Disorders in Older Men | 9/16/07 | 7/1/12 | $488,177 |
| Cauley | Jane | NIH | Study of Osteoporotic Fractures | 2/2/90 | 8/1/10 | $317,374 |
| Cauley | Jane | NIH | Training in the Epidemiology of Aging | 9/5/93 | 5/1/09 | $319,456 |
| Cauley | Jane | Novartis | Safety and Efficacy of Zoledronic Acid in Osteoporosis | 1/12/06 | 8/2/10 | $156,800 |
| Cauley | Jane | Pfizer | Comparison of Raloxifene and Lasofoxifene | 5/2/07 | 5/1/10 | $98,559 |
| Cauley | Jane | Pfizer | Postmenopausal Evaluation and Risk Reduction with Lasofoxifene | 7/2/05 | 1/1/12 | $249,949 |
| Cauley | Jane | Univ Arizona | Longitudinal Changes in Hip Geometry and Skeletal Muscle | 8/16/07 | 7/1/12 | $18,578 |
| Chaillet | John Richard | NIH | Epigenetic Variation in Mice with Defective Imprinting | 5/16/08 | 4/1/12 | $53,048 |
| Chaillet | John Richard | NIH | Mechanisms of Cytoprotection in Acute Lung Injury - Core D | 10/1/07 | 6/1/12 | $191,029 |
| Chambers | William | JMF | Novel Strategy for Glioma Specific Antigen Isolation | 12/2/05 | 12/1/09 | $113,959 |
| Chancellor | Michael | GSK | GSK non clinical agreement | 2/24/08 | 2/25/10 | $39,479 |
| Chancellor | Michael | NIH | Collaborative Urologic research in spinal cord injury | 7/2/05 | 7/1/10 | $529,636 |
| Chancellor | Michael | NIH | Collaborative Urologic research in spinal cord injury-CORE A | 7/2/05 | 7/1/10 | |
| Chancellor | Michael | NIH | Collaborative Urologic research in spinal cord injury-project 4 | 7/2/05 | 7/1/10 | |
| Chancellor | Michael | NIH | Diabetic Bladder Afferent Neuron and NFG Gene Therapy | 9/16/04 | 6/1/09 | $221,495 |
| Chancellor | Michael | NIH | Muscle Cells Mediated | 9/2/06 | 9/1/10 | $177,119 |
| Chancellor | Michael | NIH | Urologic Training Phy & Sci. | 4/2/08 | 4/1/09 | $216,215 |
| Chancellor | Michael | novartis | Clinical trial | 4/2/08 | 6/16/09 | $71,198 |
| Chancellor/Dhir | Rajiv | NIH | Collaborative Urologic Research In Spinal Cord Injury Core B1 | 8/23/05 | 7/1/10 | |
| ChancellorGetzen | Robert | NIH | Collaborative Urologic research in spinal cord injury-Project 3 | 7/2/05 | 7/1/10 | |
| Chang | Yuan | NCI | CHARACTERIZATION OF KSHV LANA2 | 7/2/06 | 2/1/09 | $334,594 |
| Chapman | Brian | NCI | Multispectral MR analysis of hepatocellular carcinoma | $163,510 | ||
| Chatta | Gurkamal | 3M Corp | A Phase II Randomized Double Blind Controlled Study to Evaluate the Safety and Efficacy of PROSTVAC VF TRICOM in Combination with GM CSF in Patients with Androgen Independent Adenocarcinoam of the Prostate | 7/9/08 | 7/8/13 | $48,320 |
| Chatta | Gurkamal | Abgenix | Clinical Trial Evaluating the Safety & Efficacy of ABX-EGF | 10/2/06 | 10/1/09 | $101,023 |
| Chatta | Gurkamal | Bioserve Biotech Ltd | A Multi Center Multi National Double Blind Randomized Phase III Study of Satraplatin Plus Prednisone or Placebo Plus Prednisone in Patients with Hormone Refractory Prostate Cancer Previously Treated with One Cytotoxic Chemotherapy Regimen | 5/7/08 | 8/2/12 | $32,702 |
| Chatta | Gurkamal | Hillman Foundation | The Immunobiology of Cancer and Aging | 7/2/08 | 7/1/11 | $76,000 |
| Chatta | Gurkamal | Millenium Pharm | Effect of Ketoconazole Administartion on the Pharmacodynamics of Bortezomib in Patients with Advanced Solid Tumors | 11/5/08 | 11/4/10 | $59,750 |
| Chatta | Gurkamal | Millenium Pharm | Repeat Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients with Relapsed Multiple Myeloma | 2/12/08 | 2/11/11 | $27,539 |
| Chatta | Gurkamal | Multiple Myeloma Research Fdtn | Bone Microenvironmental Factors In Myeloma Bone Disease | 1/2/08 | 1/1/09 | $10,788 |
| Chatta | Gurkamal | PCRN | Phase I and Pharmacokinetic Study of Daily Oral Gleevac | 8/1/06 | 12/2/09 | $72,950 |
| Chatta | Gurkamal | PCRN | Phase II Study of Alimta in Patients ..of the Urothelium | 3/2/06 | 3/1/09 | $21,262 |
| Chatta | Gurkamal | PCRN | Phase II Trial of Adjuvant Taxotere in Patients… | 6/20/06 | 6/19/09 | $31,250 |
| Chatta | Gurkamal | Pharm | Phase I Trial of Motexafin Gadolinium and Docetaxel | 7/2/07 | 3/1/09 | $126,000 |
| Chatta | Gurkamal | Sanofi | A Phase II Study of Docetaxel and Oxaliplatin in Advanced GU Malignancies Metastatic Bladder Cancer | 11/19/08 | 1/1/11 | $108,125 |
| Chatta | Gurkamal | Sanofi | A Phase II Study of Oxaliplatin and Taxotere in Androgen Independent Prostate Cancer | 11/19/08 | 1/1/11 | $108,125 |
| Chatta | Gurkamal | Scios Inc | An Open Label Study of the Efficacy Safety and Tolerability of Oral SCIO 469 in Treatment of Relapsed Refractory Patients with Multiple Myeloma | 11/5/08 | 11/4/12 | $55,147 |
| Chaudhary | Preet | NCI | Role of orf-K13, an HHV8 encoded vFLIP, in the pathogenesis of AIDS-related malignancies | 6/2/04 | 6/1/10 | $243,601 |
| Chaudhary | Preet | NIH | CASPASE 8 AND ITS HOMOLOGS IN NF-KB AND JNK ACTIVATION | 4/2/04 | 4/1/10 | $259,875 |
| Chaudhary | Preet | NIH | Genes in X-linked Ectodermal Dysplasia Receptor | 4/2/07 | 4/1/11 | $297,000 |
| Chaudhary | Preet | us Army Medical Research and Materiel Command | Role of TAJ, a new member of the TNFR Family, in prostate biology and pathogenesis of prostate cancer | 6/2/07 | 6/1/10 | $179,441 |
| Chen | Georgia | NIH | Identification of Metastasis Related Genes in Oral Cancer | 8/7/07 | 6/1/09 | $121,419 |
| Cheng | Shi-Yuan | ACS | Angiopoietin 2 and Human Glioma Invasion | 7/2/08 | 7/1/12 | $180,001 |
| Cheng | Shi-Yuan | BTS | Molecular Mechanisms of Tumor Angiogenesis | 11/1/99 | 10/31/04 | $16,666 |
| Cheng | Shi-Yuan | DOD | Suppression of Established Human Breast Tumors by Modulating Tumor Angiogenesis | 7/16/05 | 8/15/09 | $59,080 |
| Cheng | Shi-Yuan | DOD | The Roles of VEGF in Estrogen-Dependent and Estrogene-Indepent Breast Cancer | 9/2/06 | 9/1/09 | $148,640 |
| Cheng | Shi-Yuan | NCI | Angiopoietin-2 and glioma invasion | 9/2/08 | 9/1/13 | $304,425 |
| Cheng | Tao | NIH | Stem Cell Efficiency Regulated by CDK Inhitors | 9/16/05 | 9/1/09 | $321,386 |
| Cheng/Automated | Tao | NIH | Quantitation of Cellular Protein Production in Real Time | 9/2/06 | 9/1/11 | $154,385 |
| Choi | Augustine | NIH | Heme Oxygenase-1 Carbon Monoxide in Lung Vascular Injury | 7/2/07 | 7/1/12 | $347,930 |
| Choi | Augustine | NIH | Molecular Physiology of the Lung | 7/2/06 | 7/1/11 | $370,377 |
| Choi | Augustine | NIH | The Role of HEME Oxygenase in Hyperoxic Lung Injury | 1/2/06 | 12/1/09 | $141,001 |
| Cohen | Sheldon | NIH | Pre- and Post-doctoral Training Grant in Health Psychology | 07/01/01 - | 7/1/10 | $176,161 |
| Cole | Brenda | Metanexus | A Spiritual Transformation Scale for Cancer Patients | 6/2/07 | 6/1/09 | $73,341 |
| Cole | Brenda | NCI | Pilot study of a spiritually-focused intervention | 8/10/08 | 8/1/10 | $200,475 |
| Comerci | John | Merck | Randomized, Placebo-Controlled, Double Blind Study to Investigate the Incidence of HPV 16 | 7/2/06 | 9/1/11 | $91,986 |
| Costantino | Joseph | NCI | Biostatistical Center for the NSABP | 9/2/99 | 6/1/10 | $4,053,401 |
| Costantino | Joseph | NCI | Clinical Oncology Program Biostatistical Center | $5,232,677 | ||
| Croiselle | Laure | Identification of Prostate Cancer "Stem Cells" | 7/2/08 | 7/1/10 | $100,000 | |
| Crowley | Rebecca | NIH | An Intelligent Virtual Microscope Tutor on the Internet | 6/2/07 | 6/1/11 | $273,316 |
| Crowley | Rebecca | NIH/NCI | An Intelligent Melanoma Diagnostic Training System | 8/22/07 | 8/1/10 | $218,452 |
| Curran | Dennis | NIH | Radical Reactions for Natural Products | 12/2/94 | 6/31/2004 | $246,440 |
| Day | Billy | ACS | Nitric Oxide and Methyl-Nitroso-Urea Evoked Bladder Cancer | 2-Jan-07 | 1-Jan-11 | $7,383 |
| Day | Billy | ACS | Regulation of Protein Phosphatase 2A by the Tor Signalin Yeast | 2-Jul-07 | 1-Jul-11 | $7,354 |
| Day | Billy | DOD | New Advanced Technology to Improve Prediction and Prevention of Type I Diabetes | 2-Nov-07 | 1-Nov-09 | $100,000 |
| Day | Billy | NCI | Mechanisms and Prevention of Etoposide Induced Leukemia | 7/1/01 | 7/1/09 | $55,427 |
| Day | Roger | NIH/NCI | Educational Resource for Tumor Heterogeneity | 9/2/04 | 9/1/09 | $275,246 |
| Day | Billy | TRUE RESEARCH - subcontract | Role of Disrupted Iron in the Lung Injury Seen After Blast Injury and Hemorrhagic Shock/Resuscitation | 2-Nov-07 | 1-Nov-10 | $127,783 |
| DeFrances | Marie | NCI | A Novel Regulator of PI-3-Kinase in Human Liver Cancer | 2/6/08 | 2/1/12 | $274,367 |
| DeFranco | Donald | DOD | Novel Coactivators for Androgen Receptor | 3/16/06 | 3/15/09 | $182,568 |
| DeFranco | Donald | NCI | Intracellular mechanisms of glucocorticoid action | 2/16/05 | 2/1/10 | $252,368 |
| DeFranco | Donald | NIH | Hypothermia & Gene Expression After Cardiac Arrest | 10/1/06 | 7/1/10 | $9,707 |
| DeFranco | Donald | NIH | Oxidative Stress & Neurodegeneration | 7/2/04 | 7/1/09 | $260,750 |
| DeLoia | Julie | Aventis | A Phase II Trial of the Imapct of CYP3A and MDR1 Genotypes on Docetaxel Clearance in Patients with Advanced Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma Treated with Intravenous Docetaxel and Carboplatin | 4/2/08 | 5/1/10 | 141,945 |
| DeLoia | Julie | NCI | Admixture Mapping for Ovarian Cancer Susceptibility Genes | 10/1/07 | 9/30/09 | 50,000 |
| DeLoia | Julie | The Pittsburgh Foundation | The Role of Pharmacogenetics in Development of Individualized Chemotherapy for Women with Advanced Ovarian Cancer | 7/2/07 | 7/1/09 | 75,000 |
| DeLoia | Julie | UPMC CMRF | Centrosome Abnormalities in Ovarian Cancer | 7/2/07 | 7/1/10 | 12,500 |
| DeLuca | Neal | NIH | Virus-cell Interactions Affecting HSV Gene Expression | 3/2/96 | 12/1/11 | $184,440 |
| Demetris | Anthony | NCI | Altered Growth Factor Pathways in Biliary Cancer | 2/29/04 | 2/1/09 | $33,750 |
| Demetris | Anthony | NIH | Interleukin 6 and Human Bilary Epithelial Proliferation | 3/2/00 | 1/1/11 | $221,435 |
| Dew | Mary Amanda | Nat'l Marrow Donor Program | Psychosocial issues related to intimacy and | $45,154 | ||
| Dew | Mary Amanda | Nat'l Marrow Donor Program | Reactions to peripheral blood stem cell | $50,650 | ||
| Dhir | GSK | GSK Non Clinical Research Agreement | 2/25/08 | 2/24/09 | $11,250 | |
| Dhir | Rajiv | NIH | Lung Tissue Research Consortium Clinical Center RFP HR 04 08 | 1/31/08 | 1/30/13 | $64,197 |
| Dhir | NIH | MTOPS Biomarkers Unit at the University of Pittsburgh | 10/2/06 | 7/1/09 | $75,103 | |
| Dhir | URF | Urological Research Agreement | 2/2/04 | 2/1/09 | $10,000 | |
| Donnenberg | Albert | DOD | Differential MDR Activity in Breast Cancer Stem Cells | 7/31/08 | 8/30/09 | $100,983 |
| Donnenberg | Vera | Hillman Foundation | Tumor Cells in Metastatic Breast Cancer | 7/2/08 | 7/1/10 | $152,500 |
| Donnenberg | Albert | Pittsburgh Foundation | Differentiation Therapy for End Stage Cardiomyopathy A Phase I Study Using Autologous Peripheral Blood Derived Progenitor Cells | 7/2/08 | 7/1/09 | $35,281 |
| Duensing | Stefan | NIH | Genomic Instability Induced by HPV-16 E7 Oncoprotein | 7/1/05 | 4/30/10 | $790,000 |
| Duerr | Richard | NIH | Fine Mapping a Novel Inflammatory Bowel Disease Locus | 2/2/06 | 2/1/10 | $191,569 |
| Dunbar-Jacob | Jacqueline | NIH | Improving medication adherence in comorbid conditions | 9/30/04 | 9/1/09 | $517,614 |
| Edington | Howard | DOD | A Biocompatible Controlled Release Device To Function As A Structural Insert And Adjuvant Therapy | 09/02/07 | 09/01/09 | 69,032 |
| Edington | Howard | NCI | Imaging Apoptosis For Chemotherapy Responses | 05/06/08 | 04/01/10 | 11,822 |
| Egorin | Merrill | A Phase I and Pharmacokinetic Study of Gemcitabine in Combination with Oxaliplatin and Capecitbine in Advanced Solid Tumors | 4/22/08 | 5/1/12 | $13,125 | |
| Egorin | Merrill | Lilly | Intrathecal Gemcitabine Therapy for Neoplastic Meningitis | 9/19/07 | 9/20/09 | $18,616 |
| Egorin | Merrill | NCI | Gynecologic Oncology Group Pharmacology Core Laboratory | 11/2/08 | 4/1/09 | $20,694 |
| Egorin | Merrill | NIH | Preclinical Pharmacological Studies | 12/2/03 | 12/1/09 | $230,618 |
| Egorin | Merrill | Novartis | A Novartis Clinical Pharmacologic Core Facility | 10/2/06 | 10/1/09 | $136,105 |
| Egorin | Merrill | Novartis | Phase 1..Gleevac STI571 with Cisplatin and Etoposide | 12/7/05 | 10/1/09 | $12,788 |
| Egorin | Merrill | PGH FND | Isolated Hepatic Perfusion with Oxaliphatin for Colorectal Liver Metastases | 7/16/06 | 7/15/09 | $3,660 |
| Egorin | Merrill | SAIC Frederick | Measurement of IGFBP 2 and ECD in Plasma of 17AAG Patients | 8/17/08 | 8/16/10 | $51,088 |
| Egorin | Merrill | A Phase I and Pharmacokinetic Study of Gemcitabine in Combination with Oxaliplatin and Capecitbine in Advanced Solid Tumors | 4/22/08 | 5/1/12 | $13,125 | |
| Eiseman | Julie | CHP | Evaluation of Molecular Inhibitors of the c-Myc Oncoprotein | 1/20/08 | 1/19/09 | $20,001 |
| Falo | Lou | NCI | Dendritic Cell Therapy for Cutaneous T-Cell Lymphoma | 1/012005 | 1/1/14 | |
| Falo | Lou | NIH | Development of Immunotherapies for Biodefense | 8/2/07 | 8/1/11 | $296,870 |
| Falo | Louis | NIH | Immunother for Biodefense | 9/2/07 | 3/1/11 | $297,000 |
| Falo | Louis | NIH | Mechanisms of Cutaneous Immunobiology | 3/16/08 | 3/1/13 | $334,125 |
| Falo | Louis | NIH | Skin Immuniz Strategies | 7/23/07 | 6/1/10 | $236,486 |
| Ferris | Robert | FAMRI | Apoptosis of Effector T-Cell in Cancer: Implications for Immune Therapy | 7/2/07 | 7/1/10 | $108,500 |
| Ferris | Robert | NIH | American College of Surgeons Oncology group | 7/24/08 | 2/1/10 | $10,000 |
| Ferris | Robert | Targeting Human Papillomavirus E7 Protein for Immunotherapy of Head and Neck cancer Patients | 7/2/08 | 7/1/09 | $100,000 | |
| Finn | Olivera | NCI | Dendritic Cell Based Therapies for Murine Tumors | 5/2/08 | 5/1/09 | $238,090 |
| Finn | Olivera | NCI | T Cell Immunity to Epithelial Tumor Mucins | 7/6/06 | 7/1/11 | $296,687 |
| Finn | Olivera | NIH/NCI | Training in Cellular & Molecular Mechanixms of Tumor Rejection | 07/02/09 | 07/01/13 | $451,192 |
| Finn | Olivera | Immune Markers of Premalignant Disease Consortium | 07/02/09 | 07/01/12 | 100,000 | |
| Finn | Olivera | NCI | Dendritic Cell Biology and Therapy Program | 7/2/08 | 7/1/13 | $1,300,247 |
| Finn//Finn | Olivera | NCI | Dendritic Cell Biology and Therapy Program-Core A | |||
| Finn/Falo | Lou | NCI | Dendritic Cell Biology and Therapy Program-Project 3 | |||
| Finn/Finn | Olivera | NCI | Dendritic Cell Biology and Therapy Program-Project 2 | |||
| Finn/Salter | Russell | NCI | Dendritic Cell Biology and Therapy Program-Project 1 | |||
| Finn/Watkins | Simon | NCI | Dendritic Cell Biology and Therapy Program-Core C | |||
| Finn/Whiteside | Theresa L. | NCI | Dendritic Cell Biology and Therapy Program-Core B | |||
| Flynn | JoAnne | NIH | CD4 T Cells in Tuberculosis | 4/2/06 | 4/1/11 | $465,926 |
| Flynn | JoAnne | NIH | Function of CD8 T Cells in Tuberculosis | 9/2/06 | 4/1/11 | $307,717 |
| Flynn | JoAnne | NIH | Latent and Reactivation Tuberculosis | 9/20/07 | 9/1/12 | $433,410 |
| Flynn | JoAnne | NIH | Role of M3 in T Cell Development and Bacterial Infection | 8/2/00 | 6/1/10 | $90,581 |
| Flynn | JoAnne | NIH | The Dynamics of Granuloma Formation in Tuberculosis | 10/1/05 | 8/1/10 | $156,524 |
| Flynn/Albert Eins | JoAnne | NIH | Cell Migration in Tuberculosis Infection | 8/2/06 | 6/1/11 | $161,666 |
| Foon | Kenneth | Antigenetics Inc | A Phase II Study of AG 858…After Treatment with Gleevac | 2/12/08 | 2/11/12 | $22,189 |
| Foon | Kenneth | Berlex | Phase II Trial Comparing Combination Treatment With Alemtuzumab and Fludarabine…. 1st Line Therapy | 11/21/07 | 11/20/09 | $22,500 |
| Foon | Kenneth | Cephalon Inc | A Randomized Study of Oral CEP 701 Administered in Sequence with Standard Chemotherapy to Patients with Relapsed Acute Myeloid Leukemia AML Expressing FLT 3 Mutations | 12/1/08 | 11/30/12 | $76,875 |
| Foon | Kenneth | Genentech Inc | Phase II Clinical Protocol for the Treatment of Patients with Previously Untreated Chronic Lymphocytic Leukemia CLL with a Combinationpf Fludarabine Cyclophoshamide and Rituximab | 6/3/08 | 10/1/10 | $127,500 |
| Foon | Kenneth | NCI | Ganglioside GD2 as Target for immunotherapy in melanoma | 9/2/07 | 9/1/11 | $281,913 |
| Foon | Kenneth | Supergen, Inc. | A Phase II Multi Center Study of Decitabine 5 AZA 2 Deoxycytidine in Chronic Myelogenous Leukemia Chronic Phase Refractory to Imatinib Mesylate STI571 | 5/27/08 | 5/26/09 | $42,750 |
| Foon | Kenneth | Supergen, Inc. | A Phase II Multi Center Study of Decitabine 5 AZA2 Deoxycytidine in Chronic Myelogenous Leukemia Accelerated Phase Refractory to Imatinib Mesylate STI571 | 5/27/08 | 5/26/09 | $42,750 |
| Foon | Kenneth | Supergen, Inc. | A Phase II Multi Center Study of Decitabine 5 AZA2 Deoxycytidine in Chronic Myelogenous Leukemia Blast Phase Refractory to Imatinib Mesylate STI 571 | 5/27/08 | 5/26/09 | $42,750 |
| Gallion | Holly | Anna Caplan Fund | Genetic Determinants of Ovarian Cancer Development in BRCA1 and 2 Mutation | 1/2/08 | 1/1/09 | $50,000 |
| Gan | Gregory | NIH | The Function of DNA Polymerase Zeta and Its Role in DNA Damage Tolerance | 9/2/08 | 9/1/12 | $43,704 |
| Geskin | Larisa | Henry Lloyd Charitable Trust | Melanoma Awareness & Early Detection | 6/2/08 | 6/1/09 | $21,000 |
| Getzenberg | Robert | NCI | Characterization of the bladder canceer NMP, BLCA-4 | 5/23/04 | 5/1/09 | $229,384 |
| Getzenberg | Robert | NIH/NCI | Conference-Prouts Neck Prostate Cancer | 10/1/06 | 9/1/11 | $71,021 |
| Gilbert | Susan | NIH | Mechanistic Analysis of Microtuble-Based Motors | 5/2/00 | 5/1/09 | $244,174 |
| Glorioso III | Joseph | MDA | MD Cooperative Center Supplement | 1/2/08 | 1/1/11 | $86,150 |
| Glorioso III | Joseph | NIH | Gene Transfer for Pain | 10/1/06 | 9/1/10 | $111,310 |
| Glorioso III | Joseph | NIH | Gene Transfer for Prevention of Diabetic Neuropathy | 8/21/06 | 8/1/10 | $82,916 |
| Glorioso III | Joseph | NIH | Gene Transfer in Spinal Root Trauma | 12/2/06 | 12/1/10 | $30,108 |
| Glorioso III | Joseph | NIH | Retargeting HSV-1 Vectors to Motor Neurons | 7/4/06 | 7/1/10 | $355,063 |
| Gobbel | Glenn T. | NIH | Inducible DNA Repair in Cerebral Ischemia | 5/16/05 | 3/1/10 | $16,383 |
| Godfrey | Tony | NCI | Molecular Detection of Occult Metastases in Lung Cancer | 7/2/06 | 7/1/11 | $153,875 |
| Godfrey | Tony | NCI | Molecular Staging of lymph nodes in head and neck cancer | 10/1/08 | 9/1/11 | $300,448 |
| Gollin | Susanne | Comm of Pa | Characterization of the 11Q13 Amplicon in Breast Cancer | $35,000 | ||
| Gollin | Susanne | NIH | Characterization of the 11q13 amplicon in oral cancer | 8/2/06 | 8/1/11 | $324,101 |
| Gollin, S | NIH | Origin of spindle multipolarity in oral cancer cells | 7/2/08 | 5/1/13 | $103,842 | |
| Good | Walter | DOD | Automated Analysis and Display of Temporal Sequences of Mammograms | 7/2/06 | 8/1/09 | $138,408 |
| Good | Walter | NCI | Investigations of Multi-View CAD for Mammography | 2/2/04 | 2/1/09 | $154,322 |
| Gorelik | Elieser | NCI | Angiogenic Factors as Early Detection Biomarkers of Ovarian Cancer | 8/2/07 | 7/1/09 | $74,250 |
| Goyal | Rakesh | Children's Mercy Hospital & Clinics | Pediatric Bone and Marrow Transplant Consortium | 4/2/06 | 1/1/11 | $28,832 |
| Grandis | Jennifer | Aventis | Optimization of EGFR Antisense Oligonucleotides Plus Docetaxel for Treatment of Head & Neck Cancer | 7/2/06 | 7/1/09 | $114,733 |
| Grandis | Jennifer | NCI | GRPR Signaling in SCCHN:Integration with EGFR | 4/2/08 | 4/1/13 | $243,745 |
| Grandis | Jennifer | NCI | Imaging of EGFR Targeting in Head and Neck Cancer | 7/2/07 | 7/1/09 | $185,128 |
| Grandis | Jennifer | NCI | Stat Mediated TGF EGFR Signaling in SCCHN | 7/2/07 | 7/1/12 | $277,208 |
| Grandis | Jennifer | NCI | stat3 as a therapeutic target in Head and Neck cancer | 8/2/08 | 8/1/13 | $272,312 |
| Grandis | Jennifer | NIH | Research Training in Otolaryngology | 7/2/07 | 7/1/12 | $87,303 |
| Grandis | Jennifer | NCI | SPORE | 7/2/08 | 7/1/13 | $2,300,000 |
| Grandis/Bahary | Jennifer | NCI | SPORE in Head and Neck Cancer-Pilot 3 | 07/02/08 | 07/01/13 | |
| Grandis/Ferris | Jennifer | NCI | SPORE in Head and Neck Cancer-Project 3 | 07/02/08 | 07/01/13 | |
| Grandis/Grandis | Jennifer | NCI | SPORE in Head and Neck Cancer-Core A | 07/02/08 | 07/01/13 | |
| Grandis/Grandis | Jennifer | NCI | SPORE in Head and Neck Cancer-Project 2 | 07/02/08 | 07/01/13 | |
| Grandis/Hunt | Jennifer | NCI | SPORE in Head and Neck Cancer-Core B | 07/02/08 | 07/01/13 | |
| Grandis/Myers | Jennifer | NCI | SPORE in Head and Neck Cancer-Career Development | 07/02/08 | 07/01/13 | |
| Grandis/Myers | Jennifer | NCI | SPORE in Head and Neck Cancer-Developmental Research | 07/02/08 | 07/01/13 | |
| Grandis/Romkes | Jennifer | NCI | SPORE in Head and Neck Cancer-Project 1 | 07/02/08 | 07/01/13 | |
| Grandis/Schlessel | Jennifer | NCI | SPORE in Head and Neck Cancer-Core C | 07/02/08 | 07/01/13 | |
| Grandis/Siegfried | Jennifer | NCI | SPORE in Head and Neck Cancer-Project 4 | 07/02/08 | 07/01/13 | |
| Grandis/Sobol | Jennifer | NCI | SPORE in Head and Neck Cancer-Pilot 1 | 07/02/08 | 07/01/13 | |
| Greenberger | Joel S. | NCI | Gene Therapy Reduction of Radiotherapy Esophagitis | 7/2/05 | 7/1/10 | $231,371 |
| Greenberger | Joel S. | NCI | MNSOD PL Irradiation Protection of the Oral Cavity | 1/2/09 | 1/1/13 | $91,397 |
| Greenberger | Joel S. | NIH | Lung Radiation Protection by MNSOD Transgene Therapy | 4/2/06 | 2/1/10 | $161,045 |
| Greenspan | Susan | MERCK | Once Weekly Alendronate for the Prevention of Bone Loss in Men with Prostate Cancer on Androgen Deprivation | 8/31/05 | 8/20/09 | $20,072 |
| Greenspan | Susan | NIH | Osteoporosis in Older Men and Women | 1/2/07 | 12/1/11 | $79,547 |
| Greenspan | Susan | NIH | Prevention of Osteoporosis in Men with Prostate Cancer on Androgen Deprivation Therapy | 5/16/06 | 4/1/10 | $202,718 |
| Greenspan | Susan | NOVART | A Randomized, Multicenter, Double-blind, Double-dummy Study to Evaluate the Safety and Tolerability of Intravenous Zolendronic Acid Compared to Oral Alendronate in Post Menopausal Women with Moderate/Severe Osteopenia or Osteoporosis Already Treated with. | 4/2/08 | 1/1/10 | $68,950 |
| Greenspan | Susan | NOVART | Bone Loss in Men with Prostate Cancer Treated with Androgen Deprivation Therapy | 9/2/07 | 4/1/09 | $31,800 |
| Greenspan | Susan | PROCGAM | The Effect of Biophosphonate on Bone Mass, Bone Turnover and Bone Mineral Metabolism in Premenopausal and Newly Post Menopausal Women. | 11/2/06 | 2/2/09 | $87,971 |
| Greenspan | Susan | QUINT | Effect of Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women with Postmenopausal Osteoporosis | 8/2/04 | 10/1/09 | $75,691 |
| Gupta, | Phalguni | NIH | An Organ Culture to Study HIV Transmissioin | 10/1/04 | 7/1/09 | $296,280 |
| Gupta, | Phalguni | NIH | Assessment of CD8 Suppression of HIV/SIV to Vaccines | 9/16/04 | 9/1/09 | $294,243 |
| Gupta, | Phalguni | NIH | C Perfringens to Induce Anti-HIV Mucosl Immunity | 3/2/09 | 3/1/11 | $221,538 |
| Gupta, | Phalguni | NIH | Development of NNRTI's as Combination Microbicides | 10/1/06 | 8/1/11 | $319,958 |
| Gupta, | Phalguni | NIH | Topical Microbicides for Prevention of STDs/HIV | 3/2/99 | 8/1/09 | $150,733 |
| Gupta, Phalguni | Broad Medical Research Program | PSC and UC: A Model for the Study of Rare Diseases | 8/2/08 | 8/1/10 | $15,995 | |
| Gur | David | DOD | Remote Patient Management in a Mammographic Screening Enviroment in Underserved Areas | 9/2/04 | 9/1/09 | 408,375 |
| Gur | David | NCI | ROC Analysis of Imaging Systems Evaluations | 5/2/06 | 5/1/10 | $249,375 |
| Gur | David | NCI | Rule-Based CAD of Digitized Mammograms | 3/2/07 | 3/1/11 | $275,345 |
| Gur | David | NIH-NIBIB | Assessment of Variance Structure in ROC Studies | 10/1/08 | 9/1/12 | 334,125 |
| Hamilton | NIH | Univ of Washington Subcontract on "Characterization of DLB: A Collaborative Study" | 10/1/07 | 8/1/12 | $92,235 | |
| Harrison | Lee | NIH | AIDS International Training and Research Program Supplement | 9/5/93 | 5/1/09 | $328,453 |
| Harrison | Lee | NIH | Rio HVTU | 6/2/04 | 6/1/09 | $528,246 |
| Harrison | Lee | NIH | Shedding of HIV In Semen Despite Antiretroviral Therapy | 9/2/06 | 6/1/11 | $113,434 |
| He | Qiuhong | NCI | Fast 3D MR Spectroscopic Imaging of Human Breast Cancer | 4/2/09 | 4/1/14 | $371,250 |
| He | Qiuhong | NIH | Bacteria-based MR molecular imaging of tumor oxygenation | 9/16/07 | 9/1/09 | $259,875 |
| He | Qiuhong | SGK | In vivo magnetic resonance spectroscopy of breast cancer on clinical scanners | 10/2/05 | 10/1/09 | $62,456 |
| Helgeson | Vicki | NIH | Psychosocial Factors in Adolescent Adjustment to IDDM | 7/2/06 | $06/30/07 | $309,252 |
| Hendricks | NIH | Cytokines and Adhesion Molecules in HSV Keratitis | 5/2/06 | 5/1/11 | $538,751 | |
| Hendricks | NIH | Cytotoxic Lymphocytes and HSV-1 Corneal Lesion | 10/1/90 | 1/1/13 | $359,405 | |
| Herberman | Ronald B. | NCI | Development of Center for Rapid Drug Discovery | 7/2/08 | 7/1/09 | $74,250 |
| Herberman | Ronald B. | NCI | Cancer Center Support | 9/21/08 | 8/1/13 | $4,999,480 |
| Herberman | Ronald B. | Commonwealth of PA | HRFF Cellular Events in Cancer Initiation and Progression | 5/2/08 | 5/1/09 | $2,004,750 |
| Herberman | Ronald B. | Commonwealth of PA | HRFF New Approaches For Cancer Therapy | 5/2/08 | 5/1/12 | $1,856,250 |
| Herberman | Ronald B. | Commonwealth of PA | Pennsylvania Bioinformatics Consortium for Cancer Research | 7/2/06 | 7/1/09 | $1,900,655 |
| Herberman | Ronald B. | Commonwealth of PA | Pennsylvania Cancer Control Consortium | 7/2/08 | 7/1/09 | $365,000 |
| Herberman | Ronald B. | NCI | Integrating Cancer And Aging At Pitt - 2 | 10/1/07 | 9/1/12 | $395,519 |
| Herberman | Ronald B. | Pharmacia & Upjohn | Phase I Study of Celecoxib and Irinotecan with Concurrent Radiotherapy in the Pre Operative Treatment of Pancreatic Cancer | 10/15/06 | 10/14/11 | $12,500 |
| Ho | Chien | NIH | A Multidisciplinary NMR Center for Biomedical Research | 09/12/07 | 08/01/12 | 1,228,058 |
| Ho | Chien | NIH | Biophysical & Molecular Biological Studies of Hemaglobin | 5/2/83 | 5/1/10 | $642,844 |
| Ho | Chien | NIH | Conference on Magnetic Resonance in Biological Systems | 09/02/08 | 09/01/09 | $40,000 |
| Ho | Chien | NIH | New Paradigms in the Design of Blood Substitutes; Joel M. Friedman, Albert Einstein College of Medicine; Chien Ho - (Subcontract), Project 2: Design, Expression, and Properties of rHbs for HBOC's | 08/06/06 | 08/01/11 | 235,520 |
| Huang | Leaf | NIH | Inflammatory Toxicity in Non-Viral Gene Therapy | 1/2/05 | 1/1/10 | $220,347 |
| Hughes | Steven | NIH/NCI | Apoptosis in Barretts Metaplasia and Esophageal Cancer | 9/2/07 | 9/1/12 | $131,382 |
| Hughey | Rebecca | NIH | Modulation of MUC1 Mucin Trafficking | 4/2/05 | 3/1/09 | $266,299 |
| Jacobs | Samuel | Biogen Idec | A Multicenter Study to Evaluate the Effect of Rituximab Biogen Idec 102 on Primary Humoral Response Recall Response and Maintenance of Acquired Immunity to Specific Antigens | 8/4/08 | 8/3/12 | $29,850 |
| Jacobs | Samuel | Biogen Idec | Phase II Trial of CHP Rituxan followed by Zevalin and Rituxan in Untreated Patients with Follicular Non Hodgkins Lymphoma | 11/20/07 | 11/19/10 | $52,000 |
| Jacobs | Samuel | Biogen Idec | Pilot Study To Localize Zevalin in Lymphomatous Tissue Of Lymph Node and Bone | 4/6/08 | 4/5/12 | $8,000 |
| Jacobs | Samuel | IDEC | 7/26/07 | 7/25/11 | $67,486 | |
| Jacobs | Samuel | Lilly Res Labs | Companion Translational Research Protocol H3E MC JMEP | 9/16/08 | 9/15/12 | $2,676 |
| Jacobs | Samuel | NCI | UPMC Cancer Center Model for Early Phase Clinical Trials | 8/22/07 | 8/1/09 | $646,597 |
| Jenkins | Frank J. | NIH | Aging Well Sleeping Effeciently Intervention Studies Agewise | 6/2/07 | 6/1/12 | $50,585 |
| Johnson | Dan | NCI | Role of Cathepsin D in Chemotherapy Induces Cell Death | 7/2/05 | 7/1/09 | $235,463 |
| Jones | Elizabeth | US Dept of Education | Opening the Genetics Gateway with Automated Support for Student Thinking | 9/2/06 | 9/1/09 | $136,853 |
| Kalavkar | Uddhav | Hillman Foundation | Prostate cancer pilor study of afro-carribean/caucasian populations | 7/2/08 | 7/1/10 | $12,500 |
| Kalinski | Pawel | NCI | Melanoma Associated T&DC Dysfunction and Death | 3/2/08 | 3/1/09 | $301,050 |
| Kalinski | Pawel | NCI | Polarization of Dendritic Cells by CD8 T cells | 7/2/07 | 7/1/11 | $263,996 |
| Kalinski | Pawel | NIH | Dendritic Cells and Chemokines In HIV Immunotherapy | 7/2/07 | 1/1/11 | $67,622 |
| Kaminski | Naftali | NIH | New Molecular Targets in Pulmonary Fibrosis | 9/16/07 | 9/1/11 | $517,261 |
| Kane | Lawrence | Arthritis Foundation | The Role of the Akt Kinase in T Cell Activation | 7/2/08 | 7/1/09 | $70,000 |
| Khan | Saleem | Hillman Foundation | Gene Expression Analysis of HPV Associated SCCHN | 7/2/08 | 7/1/10 | $25,000 |
| Khan | Saleem | NIH | PcrA Helicase and Replication of Drug Resistance Plasmid | 4/16/07 | 4/1/09 | $223,501 |
| Kim | Ki M. | DOD | Modulation of TRAIL Cytotoxicity by Amiloride in Prostate Cancer | 11/2/08 | 12/1/10 | $83,333 |
| Kinchington | NIH | Gene Expression in HSV-1 Latency After Corneal Infection | 3/2/08 | 2/29/12 | $290,306 | |
| Kinchington | NIH | Varicella Zoster Virus Regulatory Proteins | 5/2/05 | 5/1/10 | $546,243 | |
| Kirkwood | John | Cancer Fnd Melan Res | Studies of Serum Proteomic and Tissue and Protein Array Differences Associated with the Exposure of Melanoma Patients and their Nodal Tumor Tissues to High Doses IFN | 7/2/08 | 7/1/10 | $32,500 |
| Kirkwood | John | COVANCE | A Phase II Multi center Open Label Randomized Study Evaluating the Anti-tumor Activity of sb 485232 rhIL 18….Metastatic Melanoma | 10/29/08 | 10/28/11 | $38,342 |
| Kirkwood | John | GlaxoSmithKline | A Phase I Dose Escalating Study to Assess the Safety and Pharmacokinetics of SB 485232 Administered as Five Daily Intravenous Infusions Respeated every 28 Days in Adult Patients with Solid Tumors and Lymphomas | 3/25/08 | 3/24/09 | $225,054 |
| Kirkwood | John | ICON CLINICAL RES | Phase I Open Label Non Randomized Dose Escalation Study To evaluate the Safety Toloerability Pharmacokinetics Immune Function Effects and Efficacy of Multiple Doses of cp 675 206 in Patients with Advanced Melanoma and Phase 2 Open Label Randomized Stu…. | 10/13/08 | 10/12/12 | $75,018 |
| Kirkwood | John | KUDOS | Phase I Study of Patrin in Combination with Dacarbazine in the Treatment of Patients With Solid Tumors | 10/2/07 | 2/1/09 | $134,702 |
| Kirkwood | John | Medimmune | UPCI # 03-044 A Phase II Randomized Open Label Study Evaluating the Antitumor Activity of MEDI 522 A Humanized Monocional Antibody Directed Against the Human Alpha V Beta 3 Integrin Dacarbazine in Patients With Metastatic Melanoma | 9/14/07 | 9/13/11 | $39,546 |
| Kirkwood | John | NCI | Eastern Cooperative Oncology Group | 4/17/08 | 5/1/09 | $254,167 |
| Kirkwood | John | NCI | ECOG Operations Office Melanoma Committee | 5/2/08 | 5/1/09 | $9,500 |
| Kirkwood | John | NCI | Multi Epitope Melanoma Peptide Vaccination With GM CSF | 8/6/07 | 8/1/08 | $3,000 |
| Kirkwood | John | NCI | Peptide Vaccines Plus GMCSF in Stage IV Melanoma | 8/2/04 | 7/1/09 | $223,864 |
| Kirkwood | John | NIH | Eastern Cooperative Oncology Group Prevention Member | 6/2/08 | 6/1/09 | $77,924 |
| Kirkwood | John | Protein Design Lab | Phase II Open Label Study of M200 in Combination with Dacarbazine DTIC in Patients with Metastatic Melanoma not Previously Treated with Chemotherapy | 12/9/08 | 2/1/11 | $23,829 |
| Kiss | Joseph | NIH | Transfusion Medicine/Hemostasis Clinical Research Network | 10/1/06 | 9/1/11 | $250,777 |
| Krishnamurti | Lakshmanan | Research Advisory Committee | HSCT for Hemoglobinopathy with Non-Myeloablative Therapy | 7/2/06 | 7/1/09 | $17,037 |
| Kuller | Lewis | NIH | Women's Health Initiative | 9/15/04 | 9/15/09 | $1,035,445 |
| Kuller, Lewis | NIH | Epidemiology of Cardiovascular Risk Factors in Women | 12/23/07 | 12/1/11 | $371,250 | |
| Larregina | Adriana | NCI | Use of adjuvants to improve skin genetic immunizations | $263,487 | ||
| Latimer, Jean | DOD | Genetic Analysis of DNA Repair Deficiency in Novel Non-Tumor Adjacent and Tumor Cell Lines Suggests a New Paradigm of Breast Cancer Etiology | 10/1/08 | 10/30/09 | $85,500 | |
| Latimer, Jean | DOD | Identification of Stem Cells in a Novel Human Mammary Epithelial Culture HMEC System that Reproducibly Demonstrates Ductal Organotypic Architecture in 3 Weeks | 10/1/08 | 10/30/09 | $85,500 | |
| Latimer, Jean | SGK | Molecular Mechanism of Nucleotide Excision Repair Deficiency in Novel Breast Tumor Cell Lines (The Susan G. Komen Breast Cancer Foundation) | 5/2/08 | 5/1/10 | $12,500 | |
| Lazo | John S. | NCI | Combinatorial Approaches for Novel and Anticancer Agents | 5/16/02 | 3/1/09 | $124,688 |
| Lazo | John | NCI | Natural Products Discovery Nuclear and Signaling Targets | 6/2/08 | 6/1/09 | $251,136 |
| LAZO | JOHN | NIH | Bleomycin Hydrolase and Alzheimer's Disease | 9/2/05 | 9/1/09 | $242,446 |
| LAZO | JOHN | NIH | Predoctoral Training in Pharmacological Sciences | 7/2/07 | 7/1/09 | $174,178 |
| Lee | Yong | DOD | Effect of HER 2 Neu Signaling on Sensitivity to TRAIL in Prostate Cancer | 6/2/07 | 7/1/10 | $167,859 |
| Lee | Yong | NCI | Metabolic Oxidative Stress and TRAIL Cytotoxicity | 7/2/07 | 7/1/12 | $264,330 |
| Lee | Yong | NCI | Role Of Glutaredoxin In Metabolic Oxidative Stress | 2/6/08 | 2/1/12 | $243,881 |
| Lee | Yong | PGH FND | Role Of HER2 Neu in TRAIL Based Cancer Therapy | 12/2/07 | 12/1/09 | $62,500 |
| Li | Luyuan | DOD | Anticancer Therapeutic Potential of VEGI, an Antiangiogenic Cytokine | 7/2/07 | 11/1/09 | $147,838 |
| Li | Luyuan | Hillman Foundation | Development of Anti Angiogenesis Experimental Therapeutics | 7/2/08 | 7/1/10 | $150,000 |
| Li | Luyuan | NCI | Recombinant h VEGI as an Anti Angiogenesis Therapeutic | 8/2/08 | 8/1/09 | $112,885 |
| Li | Mengfeng | Atorvastatin (Pfizer) | Atorvastatin Mechanisms of Angiogenesis Modulation and Antiangiogenic Strategies | 7/2/08 | 7/1/10 | $50,000 |
| Lieberman | Frank S. | Lilly | Intrathecal Gemcitabine Therapy for Neoplastic Meningitis | 9/19/07 | 9/20/09 | $9,000 |
| Lieberman | Frank S. | NCI | NABTC Member Institution Grant (UCSF Project Leader) | $67,568 | ||
| Lieberman | Frank S. | No | Epidemiology and Biostatistical Component of the Cohort Mortality Study | 7/2/06 | 7/1/12 | $12,800 |
| Lieberman | Frank S. | Pharmacia & Upjohn | A Phase III Randomized Open Label Study of IV Edotecarin vs Temozolomide or Carmustine BCNU or Lomustine CCNU in Patients with Glioblastoma Multiforme that has progressed recurred after Alkylator based Neo adjuvant Chemotherapy | 3/9/08 | 3/8/12 | $23,625 |
| Lillien | Laura | NIH | REGULATION OF PROGENITOR CELL MATURATION IN THE CORTEX | 12/2/07 | 12/1/11 | $173,199 |
| Ling | Bruce | NCI | Patient provider interaction and colorectal cancer screening | 9/2/08 | 9/1/10 | $148,293 |
| Ling | Bruce | NIH/NCI | Delivery and Utilization of Colorectal Cancer Screening | 8/2/05 | 8/1/10 | $112,953 |
| Liu | Dexi | NIH | Bifunctional compounds for targeted gene delivery | 9/28/07 | 8/1/11 | $284,006 |
| Liu | Dexi | NIH | New polymeric carriers for pulmonary gene delivery | 7/2/08 | 5/1/12 | $371,250 |
| Lokshin | Anna | DOD | Integrated Development of Serum Molecular Markers for Early Diagnosis of Breast Cancer | 8/19/07 | 8/18/10 | $101,730 |
| Lokshin | Anna | Hillman Foundation | Luminex Analysis of Multiple Serum Markers for Early Diagnosis of Ovarian Cancer | 7/2/08 | 7/1/09 | $138,000 |
| Lokshin | Anna | NCI | Angiogenic Factors As Early Markers Of Ovarian Cancer | 8/2/07 | 7/1/09 | $6,580 |
| Lokshin | Anna | NCI | Identification of Early Markers for Ovarian Cancer | 7/2/07 | 7/1/11 | $329,955 |
| Lu | Binfeng | NIH | Regulation of the MAP Kinase Pathway in the CD4+ T cells | 4/2/07 | 4/1/12 | $119,895 |
| Luketich | James | Eli Lilly | A Randomized Phase II Trial to Outline the Efficacy of Gemcitabine Containing Regimens When Used as Preoperative Chemotherapy in Patients with Stage I and II Non Small Cell Lung Cancer | 5/27/08 | 5/26/10 | $27,500 |
| Luketich | James | NCI | Use of Quantitative RT PCR for Staging Esophageal Cancer | 3/10/05 | 3/1/09 | $341,426 |
| Luketich | James | Stryker Corporation | Partnership With Stryker | 1/2/03 | 1/1/10 | $64,261 |
| Lunsford | L. Dade | The Copeland Fund Grant for Research in Cranial Surgery | $214,733 | |||
| Luo | Jianhua | DOD | Defining the role of myopodin in invasive prostate cancer. | 3/2/07 | 4/1/10 | $186,122 |
| Luo | Jianhua | NCI | The Role of Myopodin in Invasive Prostate Cancers | 7/2/07 | 7/1/12 | $264,348 |
| Manuck | Stephen | NIH/Carnegie Mellon University | Pre and Post Doctoral Training in Health Psychology | 9/16/99 | 7/1/10 | $71,899 |
| Marcus | Marsha | NIH | Family-based treatment of severe pediatric obesity | 6/2/05 | 6/1/09 | $121,310 |
| Marcus | Marsha | NIH | Obesity/Nutrition research center | 4/2/07 | 4/1/12 | $54,500 |
| Marsh | Gary | Eli Lilly & Co. | Cohort Mortality Study of the Clinton and Lafayette, IN Plants | 9/2/00 | 8/1/09 | $75,385 |
| Marsh | Gary | Highmark BlueCross BlueShield | Program of Biostatistical Support | 3/2/02 | 3/1/10 | $63,036 |
| Marsh | Gary | Owens Corning | Mortality Surveillance and Epidemiologic Support Program for Owens Corning | 1/2/06 | 1/1/10 | $599,189 |
| Marsh | Gary | Pennsylvania Cancer Control Program | Medical Surveillance Program and Epidemiology Study for Former Chemical Workers at High Risk of Developing Bladder Cancer | 7/2/05 | 7/1/10 | $144,425 |
| Marsh | Gary | Pratt & Whitney | Epidemiology and Biostatistical Component of the Pratt & Whitney Cohort Mortality Study | 7/16/06 | 7/1/12 | $1,647,776 |
| Marsland | Anna | NIH | Psychological stress and immune response to vaccination | 9/2/07 | 6/1/12 | $343,400 |
| McClane | Bruce | NIH | Clostridium perfringens Type B-D Virulence Plasmids | 7/2/07 | 1/1/12 | $391,621 |
| McClane | Bruce | NIH | Mechanism of Action of C Perfringens Enterotoxin | 4/2/04 | 4/1/09 | $220,025 |
| Mellors | John | NIH | Alcohol Associated Outcomes Among HIV +/- Aging Veterans | 10/1/05 | 9/1/10 | $14,543 |
| Mellors | John | NIH | Training in AIDS and Molecular Microbiology/Epidemiology | 8/2/04 | 8/1/09 | $155,996 |
| Mello-Thoms | Claudia | NCI | Perception and Inter -observer variability in mammography | 8/2/08 | 8/1/09 | $153,968 |
| Meltzer | Carolyn | NIH | Age/Sex Effects on the Central Serotonin System | 5/6/08 | 4/1/12 | $463,212 |
| Michalopoulos | NCI | HGF and Signaling Pathways in Hepatic Tissue Assembly | 4/2/08 | 4/1/13 | $298,701 | |
| Michalopoulos | NCI | HGF in Liver Development,Regeneration and Neoplasia | 1/2/06 | 1/1/12 | $325,623 | |
| Michalopoulos | NCI | Molecular Reclassification of Prostatic Cancer | 8/30/04 | 2/1/09 | $677,203 | |
| Milcarek | Christine | NCI | Polyadenylation Factors in B-Cells, Lymphoma & Myeloma | 1/2/07 | 2/1/12 | $260,239 |
| Modugno | Francesmary | DOD | Novel Risk Factors and Potential Early Detection Markers for Ovarian Cancer | 8/2/06 | 8/1/10 | $54,724 |
| Modugno | Francesmary | DOD | Prospective Evaluation of Hormone Replacement Therapy, Body Mass Index, Estrogen Tabolism and Breast Cancer Risk | 7/2/06 | 7/1/09 | $124,369 |
| Modugno | Francesmary | NCI | Symposia Series Ovarian cancer Prevention of The Disease and Its Recurrence | 7/2/08 | 7/1/10 | $30,000 |
| Modugno | Francesmary | NCI | The Role of Prolactin in Postmenopausal Breast Cancer | 9/15/08 | 9/1/10 | $74,250 |
| Modugno | Francesmary | NIH/NCI | Ovarian Cancer Risk and Survival in BRC A Carriers | 7/2/04 | 7/1/09 | $138,193 |
| Monaco | Valerie | NIH | Clinical Decision-Making Using a Data-Driven Display | 10/1/07 | 9/30/10 | $685 |
| Monga | Paul | ACS | The Role of WNT BETA Catenin and HGF in Hepatopcarcinogenesis | 7/2/07 | 7/1/11 | $179,660 |
| Monga | Paul | NIH | Role of WNT Beta Catenin Signaling in Liver Development | 1/2/08 | 1/1/13 | $263,318 |
| Montelaro | Ronald | NCI | Cellular & Molecular Biology of EIAV Replication | 3/2/06 | 3/1/10 | $294,437 |
| Montelaro | Ronald | NIH | Domain-Specific Serology for SIV/SHIV Vaccine Evaluation | 10/1/04 | 8/1/09 | $266,812 |
| Montelaro | Ronald | NIH | EIAV Envelope Variation and Vaccine Efficacy | 7/2/07 | 1/1/12 | $617,537 |
| Montelaro | Ronald | NIH | Molecular Microbial Persistence and Pathogenesis | 7/2/05 | 7/1/10 | $279,338 |
| Moore | Patrick | NCI | Herpesvirus Persistence and Oncogenicity | 8/2/06 | 8/1/09 | $241,555 |
| Murphy-Corb | Michael | NIH | Adjuvanted Vaccine Strategy for Immunotherapy of HIV | 1/2/08 | 1/1/11 | $311,320 |
| Murphy-Corb | Michael | NIH | Vaccines and Immune Based Therapy for Biodefense | 1/7/07 | 2/29/12 | $45,948 |
| Nelson | Scott | ACS | Synthesis and Evaluation of Small Moleculae Microtubule Stabilizing Agents | 7/2/07 | 7/1/09 | 212830 |
| Nelson | Scott | Eli Lilly | Eli Lilly Award | 11/16/05 | 12/1/09 | $50,000 |
| Nelson | Scott | NSF | Catalytic Asymetric Acyl Halide-Aldehyde Cyclocondesation & Claisen Rearrangements | 7/2/07 | 7/1/10 | $140,000 |
| Nelson | Joel | abbott | Preclinical evaluatio ZD1611 | 9/5/07 | 8/16/09 | $200,000 |
| Ness | Roberta | NCI | Inflammation and Ovarian Cancer | 5/13/07 | 5/1/12 | $544,140 |
| Nichols | Mark D. | Hillman Foundation | RHP Random Hairpin Production a Breakthrough in Functional siRNA Genomics | 7/2/08 | 7/1/10 | $12,500 |
| Okada | Hideho | Doris Duke | Isolation of Glioma Antigens From IL-4 Vaccine Patients | 7/2/05 | 7/1/10 | $108,000 |
| Okada | Hideho | JSMF | Identification and Characterization of Glioma CTL Epitopes | 10/2/07 | 10/1/11 | $108,058 |
| Okada | Hideho | National Brain Tumor Foundation | Vaccination with Glioma Associated Antigen Peptides in Nf1 and Trp53 Mutant Mice that Develop Spontaneous Glioblastoma | 10/22/04 | 7/22/09 | $13,500 |
| O'Keefe | Denise | DOD | Genetic and epigenetic mechanisms regulating gene expression profiles in prostate cancer | 2/2/08 | 3/1/11 | $334,125 |
| Okobia | Michael | DOD | Estrogens, Genetic Polymorphisms and Breast Cancer Risk | 7/2/06 | 7/1/09 | $46,930 |
| Onate | Sergio A. | ACS | Role of Steroid Receptor Co-Activators in Prostate Growth and Development | 7/2/05 | 7/1/09 | $176,158 |
| Parker | Robert | NCI | Optical Spectroscopy for Management of Cancer Treatment | 9/2/07 | 9/1/12 | $1,079,317 |
| Parker | Robert | NSF | Pillars of Chemical Engineering: A Block-Scheduled Curriculum | 9/2/07 | 9/1/10 | $437,519 |
| Parker | Robert | Whitaker Foundation | Model-based Optimal Scheduling for Cancer Chemotherapy | 1/2/06 | 9/1/09 | $80,000 |
| Pflug | Beth | NCI | Fatty acid synthase in prostate tumorgenesis | 2/2/08 | 2/1/12 | $237,091 |
| Pilewski | Joseph | CYSFIB | Exhaled Carbon Monoxide as a Clinical Tool in CF | 4/2/07 | 4/1/09 | $72,360 |
| Pipas | James M | NCI | Expression of Simian virus 40 T antigens in intestine | 7/2/07 | 7/1/12 | $326,070 |
| Pipas | James M | NCI | SV40 T Antigen role in virus growth and transformation | 7/2/89 | 4/1/10 | $273,154 |
| Pitt | Bruce | NIH | Metallionein and Reactive Oxygen | 9/2/91 | 4/1/12 | $250,000 |
| Plevy | Scott | PROTEIN | A Phase I/II Partially Randomized, Open-Lable Study of Visiliumab in Patients with Severe Ulcerative Colitis Refractory to Intravenous Corticosteroids | 1/2/08 | 4/1/10 | $9,043 |
| Pollack | Ian F. | NCI | Novel Treatment Approaches for Pediatric Brian Tumors | 4/2/08 | 4/1/13 | $190,978 |
| Pollack | Ian F. | NIH | Molecular Markers as Predictors of Outcome in Gliomas | 4/2/06 | 4/1/10 | $267,770 |
| Pollack | Ian F. | NIH | Novel Stratagies for Brain Tumor Therapy | 7/2/06 | 6/1/11 | $1,290,953 |
| Pollack/Glorioso | Ian/Joseph | NIH | Novel Strategies for Brain Tumor Therapy-Project 3 | 7/2/06 | 6/1/11 | |
| Pollack/Okada | Ian/Hideho | NIH | Novel Strategies for Brain Tumor Therapy-Project 2 | 7/2/06 | 6/1/11 | |
| Pollack/Pollack | Ian/Ian | NCI | Novel Strategies for Brain Tumor Therapy-Project 1 | 7/2/07 | 6/1/11 | |
| Pollack/Pollack | Ian/Ian | NIH | Novel Strategies for Brain Tumor Therapy-Core A | 7/2/06 | 6/1/11 | |
| Pollack/Watkins | Ian/Simon | NIH | Novel Strategies for Brain Tumor Therapy-Core B | 7/2/06 | 6/1/11 | |
| Pollack/Whiteside | Ian/Theresa | NIH | Novel Strategies for Brain Tumor Therapy-Core C | 7/2/06 | 6/1/11 | |
| Pound | Charles | ctcr | clinical trial | 3/26/07 | 2/29/24 | $50,000 |
| Raab | Stephen | JHF | Improving Patient Safety by Redesigning Pathology Practice | 7/2/07 | 7/1/09 | $64,250 |
| Raab | Stephen | NIH | Improving Patient Safety by Examining Pathology Errors. | 9/13/06 | 9/1/11 | $628,254 |
| Rabinowich | Hannah | DOD | Mechanisms of Resistance to Granzyme B-Mediated Apoptosis in Breast Cancer | 7/2/06 | 7/1/09 | $143,431 |
| Rabinowich | Hannah | NCI | Novel Pathways In Lymphocyte Granule Mediated Cytoxicity | 7/2/08 | 7/1/13 | $293,841 |
| Ragni | Margaret | BAXTER | Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins: Severe Hemophilia A Patients Undergoing Surgical or Invasive Procedure | 1/2/06 | 1/1/10 | $7,459 |
| Ragni | Margaret | CHIRON | Extended Safety Evaluation in Subjects Who Have Participated in Chiron Technologies Center for Gene Therapy Retrovirus Protocols | 4/26/06 | 4/25/17 | $1,136 |
| Ragni | Margaret | NIH | Impact of HIV on Hepatic C Infectin in Hemophilia | 4/12/05 | 4/1/09 | $372,424 |
| Rajasekaran | Baskaran | ACS | Signaling by Ataxia Telangiectasia Gene Product | 1/2/06 | 1/1/10 | $213,486 |
| Rajasekaran | Baskaran | NIH | Functional Role of ATM-Abl-RNAP II Signaling Pathway | 9/11/05 | 9/1/10 | $223,500 |
| Ramanathan | Ramesh | Phase I/II Trail of Alimta + Ironotecan | 7/25/07 | 7/24/10 | $21,666 | |
| Ramanathan | Ramesh | Alza | Phase I..Safety and PKs of Stealth CKD 602 | 9/1/07 | 8/1/11 | $53,512 |
| Ramanathan | Ramesh | AMGEN | Phase II Multicenter Single Arm Clinical Trial of AMX EGF Monotherapy in Subjects with Metatstatic Colorectal Cancer Following Treatment with Fluoropyrimidine Irinotecan and Oxaliplating Chemotherapy | 8/12/08 | 8/11/12 | $41,962 |
| Ramanathan | Ramesh | Astra Zeneca | Phase II Study of ZD1839 IRESSAO and Docetaxel Taxotereo in Advanced Pancreatic Carcinoma | 4/15/08 | 4/14/12 | $68,513 |
| Ramanathan | Ramesh | Genentech Inc | Phase II Study of the A ICOX Regimen Consisting of Bevacizumab Avastina Intermittent Dose Capecitabine Xelodaa and Oxaliplatin Eloxtina in Patients with Untreated Advanced Colorectal Cancer | 12/14/08 | 12/2/11 | $70,000 |
| Ramanathan | Ramesh | NOVARTIS | A Randomized Double Blind Placebo Controlled Phase III Study of Oxaliplatin 5 Fluorouracil Leucovorin with PTK787 ZK 222584 or Placebo in Patients with Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum | 11/2/06 | 1/1/10 | $15,920 |
| Ramanathan | Ramesh | PCRN | Phase III Trial of Altima Plus Gemzar Versus Gemzar Patients with Unrestrictable or Metastatic Cancer of the Pancrease | 5/2/06 | 5/1/09 | $109,666 |
| Ramanathan | Ramesh | PRI | …Three Regimines of Eloxatin Plus Fluoropyrimidine | 2/21/07 | 2/20/09 | $43,125 |
| Ramanathan | Ramesh | Wyeth | Phase II..MAC321 for Colorectal Cancer | 6/2/07 | 6/1/10 | $42,153 |
| Ramanathan/Zam | William | Alza | Phase I..Safety and PKs of Stealth CKD 602 | 9/1/07 | 8/1/11 | $13,344 |
| Rapic Otrin | Vesna | Pittsburgh Foundation | The Structure of UV DDB A Protein Which is Defective in Cancer Prone Xeroderma Pigmentosum Patients | 7/2/08 | 7/1/10 | $46,255 |
| Ray | Prabir | NIH | Chemokines and Immune Regulation in the Lung | 12/16/07 | 12/1/12 | $178,444 |
| Ray | Prabir | NIH | KGF and Protection from Hyperoxic Lung Injury | 7/2/05 | 6/1/09 | $307,085 |
| Ray | Anuradha | NIH | Mechanisms of Antigen-Induced Tolerance in the Lung | 1/2/05 | 1/1/10 | $356,964 |
| Ray | Anuradha | NIH | The Differentiation and the GATA-3/T-Bet Balance | 4/2/06 | 3/1/11 | $224,000 |
| Reddy | Sakamuri | DOD | Measles Virus Nucleocapsis MVNP Gene Expression and RANK Receptor Signaling in Osteoclast Precursors | 10/2/07 | 10/1/11 | $181,809 |
| Redinbaugh | Ellen | NIH | An Intervention to Improve End-of-Life Symptom Distress | 9/29/05 | 9/1/09 | $62,749 |
| Redner | Robert | Hematology Oncology Fellowship Program | 10/2/07 | 9/21/09 | $40,000 | |
| Reinhart | Todd | NIH | An Adjuvanted herapeutic DNA Vaccine for AIDS | 7/2/07 | 1/1/11 | $133,639 |
| Reinhart | Todd | NIH | Chemokine Modulation during SIV Invfection and AIDS | 3/2/09 | 3/1/14 | $385,050 |
| Reinhart | Todd | NIH | IL-23/IL-17 and Lung Host Defense | 12/14/08 | 12/1/13 | $56,614 |
| Resnick | Neil | JEWHLTH | Geriatrics Teaching Award | 1/2/05 | 1/1/10 | $30,000 |
| Resnick | Neil | Jewish Health Care Foundation | Geriatrics Teaching Award | 1/2/05 | 1/1/10 | $30,000 |
| Resnick | Neil | Jewish Health Care Foundation | Geriatrics Teaching Award | 1/2/05 | 1/1/10 | $30,000 |
| Resnick | Neil | NIH | Enhancing Non-PharmacologicTherapy for Incontinence | 10/1/07 | 9/1/12 | $268,033 |
| Ridgway | William | NIH | Mechanism of NOD.IDD3/10/17/18/9 (LD) Liver Disease | 9/2/06 | 7/1/10 | $269,666 |
| Rinaldo | Charles | NCI | Cytotoxic T cell responses to HHV-8 | 7/2/03 | 1/1/12 | $450,613 |
| Rinaldo | Charles | The Adult AIDS Clinical Trials Group | Pittsburgh AACTG Immunology Support Laboratory | 1/2/08 | 1/1/10 | $280,000 |
| Rinaldo | Charles | NIH | Antigen Delivery for Adjuvant HIV Immunotherapy-TOTALS | 10/1/02 | 9/1/09 | $1,487,476 |
| Rinaldo | Charles | NIH | Dendritic Cell Based Immunotherapy for HIV Infection-TOTALS | 9/16/07 | 3/1/11 | $1,499,999 |
| Rinaldo | Charles | NIH | Immunopathology of HIV-1 VPR | 4/2/06 | 4/1/10 | $295,445 |
| Rinaldo | Charles | NIH | Solid Organ Transplantation in HIV: Multi-Site Study | 7/2/07 | 7/1/12 | $235,995 |
| Rinaldo | Charles | NIH | Anti-HIV T Cell Responses during Antiviral Drug Therapy | 8/2/01 | 7/1/13 | $334,125 |
| Rinaldo | Charles | NIH | Subcontract with UCSF on "Solid Organ
Transplantation in HIV: Multi- Site Study" |
8/16/07 | 2/1/12 | $258,023 |
| Rinaldo | Charles | NIH | Multicenter AIDS Cohort Study | 5/4/08 | 5/1/13 | $3,050,550 |
| Rinaldo/Barratt-B | Simon | NIH | Antigen Delivery for Adjuvant HIV Immunotherapy-Project 1 | 10/1/02 | 9/1/09 | |
| Rinaldo/Barratt-B | Charles | NIH | Dendritic Cell Based Immunotherapy for HIV Infection-Project 1 | 9/16/07 | 3/1/11 | |
| Rinaldo/Donnenb | Albert | NIH | Antigen Delivery for Adjuvant HIV Immunotherapy-Project 3 | 10/1/02 | 9/1/09 | |
| Rinaldo/Falo | Lou | NIH | Antigen Delivery for Adjuvant HIV Immunotherapy-Project 2 | 10/1/02 | 9/1/09 | |
| Rinaldo/Falo | Charles | NIH | Dendritic Cell Based Immunotherapy for HIV Infection-Project 2 | 9/16/07 | 3/1/11 | |
| Rinaldo/Gambotto | Charles | NIH | Dendritic Cell Based Immunotherapy for HIV Infection-Core B | 9/16/07 | 3/1/11 | |
| Rinaldo/Murphy- | Michael | NIH | Antigen Delivery for Adjuvant HIV Immunotherapy-Core B | 10/1/02 | 9/1/09 | |
| Rinaldo/Rilddler | Sharon | NIH | Antigen Delivery for Adjuvant HIV Immunotherapy-Project 4 | 10/1/02 | 9/1/09 | |
| Rinaldo/Rinaldo | Charles | NIH | Antigen Delivery for Adjuvant HIV Immunotherapy-Core A | 10/1/02 | 9/1/09 | |
| Rinaldo/Rinaldo | Charles | NIH | Dendritic Cell Based Immunotherapy for HIV Infection-Core A | 9/16/07 | 3/1/11 | |
| Rinaldo/Rinaldo | Charles | NIH | Dendritic Cell Based Immunotherapy for HIV Infection-Project 3 | 9/16/07 | 3/1/11 | |
| Rinaldo/Rinaldo ( | Charles | NIH | Dendritic Cell Based Immunotherapy for HIV Infection-Core D | 9/16/07 | 3/1/11 | |
| Rinaldo/Robbins | Paul | NIH | Antigen Delivery for Adjuvant HIV Immunotherapy-Core D | 10/1/02 | 9/1/09 | |
| Rinaldo/Watkins | Simon | NIH | Antigen Delivery for Adjuvant HIV Immunotherapy-Core C | 10/1/02 | 9/1/09 | |
| Rinaldo/Watkins | Charles | NIH | Dendritic Cell Based Immunotherapy for HIV Infection-Core C | 9/16/07 | 3/1/11 | |
| Ritchey | Kim | Katie Westbrook Cancer Research Foundation | Katie's Fund: The Katie Westbrook Cancer Research Fund | 9/2/04 | 9/1/11 | $30,000 |
| Ritchey | Kim | Katie Westbrook Cancer Research Foundation | Katie's Fund: The Katie Westbrook Cancer Research Fund | 9/2/04 | 9/1/11 | $30,000 |
| Robbins | Paul | Am Diabetes Assoc | Development of Methods for Insulin Gene Transfer to K Cells in vivo | 1/2/08 | 7/1/10 | $93,709 |
| Robbins | Paul | DOD | Peptide Transduction-based Therapies for Prostate Cancer | 5/2/07 | 6/1/10 | $157,575 |
| Robbins | Paul | DOD | Protein Transduction-based Therapies for Breast Cancer | 6/24/07 | 7/23/10 | $136,295 |
| Robbins | Paul | MDA | MD Cooperative Center Supplement | 1/2/08 | 1/1/11 | $95,503 |
| Robbins | Paul | NIH | Humoral and Cellular Tolerization Approaches Against Autoimmunity | 10/1/07 | 9/1/12 | $199,063 |
| Rockette | Howard | Cystic Fibrosis | Clinical Studies Core | 8/2/06 | 8/1/09 | $63,000 |
| ROMERO | GUILLERMO | NIH | The role of phosophatidic acid in growth factor signaling | 6/2/04 | 6/1/09 | $205,563 |
| Roodman | David | Celgene | CC5013 + Dexamethasone vs Dexamethasone for Myleoma | 5/28/07 | 1/1/10 | $81,415 |
| Roodman | David | Celgene | Phase II Trial of Melphalan and Prednisone w/wo Thalidomide | 4/4/07 | 6/10/09 | $77,500 |
| Roodman | David | Celgene | Thalidomide + Dexamethasone v Dexamethasone for Myleoma | 5/28/07 | 1/1/12 | $16,041 |
| Roodman | G. David | NIH | Developmental Aspects of Osteoclast Formation in Vitro | 10/1/05 | 4/1/10 | $260,602 |
| Roodman | G. David | NIH | Flavopirido/Bortezomib in Myeloma/B Cells Neoplasms | 6/16/08 | 6/1/10 | $58,236 |
| Roodman | G. David | NIH | Pathobiology of Paget's Disease | 9/30/07 | 9/1/12 | $1,680,765 |
| Roodman | G. David | NIH | Pathobiology of the Osteoclast in Paget's Disease | 9/2/02 | 9/1/11 | $323,681 |
| Roodman | G. David | VA | Role of MIP-1 Alpha in Myeloma Bone Disease | 1/3/06 | 10/1/10 | $112,212 |
| Rosenzweig | Margaret | NCI | Disparate MBC symptom severity and mgmt barriers | 8/2/07 | 8/1/12 | $133,301 |
| Saunders | William | March of Dimes | Role of Novel BMPDLP in the Induction of Meiosis in 5 Cerevisiae | 6/2/07 | 6/1/10 | $75,000 |
| Schatten | Gerald | NIH/NCRR | Improvement of Institutional Animal Resources | 9/16/07 | 9/15/09 | 311,147 |
| Schatten | ||||||